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ABSTRACT
Death rates for breast cancer have steadily decreased in women due to early
detection, such as mammography, and improved treatments. Despite the benefit of
mammography, many women are not up-to-date on screening and do not receive timely
follow-up after abnormal mammogram finding. Breast cancer is a major contributor to
morbidity and mortality among women in South Carolina. To reduce the disproportionate
burden of breast cancer and cervical cancer among women in South Carolina, the South
Carolina Best Chance Network (BCN) was established to provide service delivery and
ensures timely and complete diagnostic follow-up and treatment initiation for
underserved women.
The purpose of this dissertation was to examine whether travel distance to the
screening provider and mammography facility are associated with completion of
abnormal mammography follow-up, breast cancer stage at diagnosis, and mortality
among women in the BCN. Women enrolled in BCN between 1996 and 2009 were
included in the study. Cox proportional hazard modeling was used to assess the
relationship between travel distance and time to resolution. Multivariable logistic
regression was used to assess the association between travel distance and breast cancer
stage at diagnosis. Cox proportional hazard modeling and Kaplan-Meier survival
methods were used to determine breast cancer-specific and all-cause survival
probabilities.

v

Women who lived farther from their diagnosing mammography facility had
longer day to resolution compared to those who lived the closest (p=0.05). African
American women had significantly longer day to resolution compared to European
American women. There was no association between travel distance to the screening
provider, mammography facility and breast cancer stage at diagnosis. There was also no
association between travel distance and breast cancer-specific and all-cause mortality.
Travel distance from patient’s residence to the diagnosing mammography facility
may have an impact on the completion of abnormal mammographic finding. However,
living farther from the screening provider and mammography facility do not increase
late-stage breast cancer at diagnosis and mortality among women in BCN. Support to the
BCN program to expand services should be promoted to reduce the disparity in days to
completion of abnormal mammographic finding. Capturing an accurate measurement of
travel distance/time will help better understand whether location of the health facilities
affects breast cancer outcome.
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CHAPTER 1
INTRODUCTION
This chapter presents an overview of the problem; it begins with breast cancer
statistics, mammography screening and utilization, follow-up after abnormal
mammography, breast cancer stage at diagnosis, breast cancer problem in South Carolina,
the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and an
introduction to Geographic Information System (GIS). It continues with the purpose and
specific aims, and the significant of the dissertation. Lastly, it ends with a summary of the
chapter.
Statement of the Problem
Breast Cancer Statistics
Breast cancer is the most common type of cancer among women and ranks second
as a cause of death from cancer in the United States (1). About 1 in 8 women born today
will be diagnosed with breast cancer at some point during their lifetime (2). In 2012, the
American Cancer Society estimates approximately 226,870 new cases and 39,920 deaths
from breast cancer among women in the United States (1). From 2002-2006, the ageadjusted incidence of breast cancer was 121.8 per 100,000 women and the age-adjusted
death rate was 24.5 per 100,000 women per year (3). Among women in the United States,
the overall 5-year relative survival rate is ~90%, a significant improvement from 63% in
the early 1960s (1).
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Mammography Screening and Utilization
Death rates for breast cancer have steadily decreased in women due to earlier
detection, such as mammography, and improved treatments (4-9). Mammography is the
single most effective method of early detection for breast cancer. It can identify the
cancer at an early stage, when treatment is more effective (1). The American Cancer
Society screening guidelines recommend that average-risk women aged 40 and older
receive mammography screening on an annual basis (1). About 38%-54% of women do
not maintain annual adherence to screening mammograms (10, 11), and only 49% having
received screening when using a biennial schedule (11). Annual mammography with
adequate follow-up is estimated to result in reductions in mortality ranging from 25% to
44% (6, 7, 12-15). Mammography is a highly accurate screening tool, but like most
medical tests, it does not have perfect sensitivity and specificity. Generally, reported
positive predictive values ranges from 78% to 90% (1, 16, 17). One drawback of
mammography is the false positive results. One large study found that over a 10-year
period of annual mammogram screenings, the chance of having a false positive result was
close to 50% (18).
Despite the benefit of mammography, many women are not up-to-date on
screening (10, 11, 19, 20) and in fact, mammography uses have been declining in the past
years (10, 21-23). This indicator of inadequate screening is associated with late stage
breast cancer at diagnosis (24-26), which contributes largely to survival and mortality.
Factors associated with mammography utilization have been scrutinized in numerous
studies, which includes patients characteristics, socioeconomic status, insurance status,
having a primary health care provider, recommendations for screening from primary
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health care providers, lack of transportation/or time and distance, language barriers,
concern about the effects of radiation, and fear of cancer (27-36).
Abnormal Mammography and Follow-up
Mammography screening for breast cancer reduces mortality from breast cancer
when women receive timely follow-up and appropriate treatment (7, 15). Mammogram
results are interpreted by radiologists using the American College of Radiologist Breast
Imaging Reporting and Data System (BIRADSTM) categories: 0 – “incomplete”; 1“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious abnormality”; 5-Highly
suspicious of malignancy”; and 6-“Known biopsy proven malignancy” (37). A category
of 3, 4, and 5 will require additional diagnostic procedures to determine the presence or
absence of the disease (37). About 9%-15% of women who receive mammography
screening have abnormal finding that require further testing (38), and approximately
30%-50% never return for follow-up testing (39, 40). Incomplete screening and delayed
abnormal follow-up can negate the potential benefits of identifying breast cancer at an
early stage, where treatment is more effective and cure is more likely. Though many
factors predicting incomplete and delayed abnormal breast cancer screening follow-up
have been examined (26, 39-50), none has looked at distance to mammography facilities
and completion of abnormal breast cancer screening follow-up.
Breast Cancer Stage of Diagnosis
Breast cancer stage at diagnosis is an important factor in survival and mortality.
The 5-year relative survival rates among women whose breast cancer is diagnosed while
in the regional stage are nearly four times greater than those of women whose cancer has
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spread to distant (distant stage) lymph nodes or organs at the time of diagnosis (84% vs.
23%) (2). Studies consistently show that low-income, health insurance status,
community poverty, and racial/ethnic minorities are more likely to be diagnosed with
late-stage breast cancer (51-57). Over the past decades, researchers have also explored
geographic proximity to health care or mammography locations and breast cancer stage at
diagnosis (58-66), which has found to be an important predictor of breast cancer stage at
diagnosis.
Breast Cancer in South Carolina
In 2012, the American Cancer Society estimated 3,570 women in the state of
South Carolina were diagnosed with breast cancer and about 18% of the diagnosed
women died of the disease (1). Breast cancer is the most common cancer diagnosed and
is the second largest cause of cancer deaths among women in South Carolina (67).
Statewide, the age-adjusted incidence of breast cancer from 2002-2006 have remained
stable at around 119 per 100,000 women (1), with a higher age-adjusted incidence among
European American women compared to African American women (127.6 and 111.3 per
100,000 women, respectively) (68). The burden of this disease is heavily on low income,
uninsured African American (51, 69).
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and
South Carolina’s Best Chance Network (BCN)
Minority, uninsured, and lower socioeconomic status women often do not have
access to early detection (28, 36). These women are less likely to utilize mammography
screening (28-32, 36), less likely to have timely and complete follow-up after an
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abnormal mammography screening (39-41, 44), more likely to be diagnosed with
advanced-stage breast cancer (51, 54, 56), and have poorer survival (51-53). To reduce
the disproportionate burden of breast cancer and cervical cancer among these women, the
U.S. Congress authorized the National Breast and Cervical Cancer Early Detection
Program (NBCCEDP) in 1990 (70). Since then, the program has established service
delivery and ensures timely and complete diagnostic follow-up and treatment initiation
for underserved women screened through the program.
South Carolina’s NBCCEDP, also known as the Best Chance Network (BCN), is
a network of public and private partnerships with more than 250 health care providers
offering screening and follow-up services to disadvantaged women in the State. At close
to 18% (71), South Carolina has one of the highest proportions of uninsured women in
the nation, which majorities of these women are eligible to enroll in the program. The
majority (60%) of the women in BCN are African American and reside in rural counties
(72). The BCN offers an unique opportunity to explore the relationship between distance
to the provider, mammography facilities, and breast cancer morbidity and mortality
among women with equal access to screening services.
Geographical Information Systems (GIS)
Geographical Information System (GIS) is a system designed to input, store, edit,
retrieve, analyze, and output geographic data information (73). It allows individuals to
view, understand, question, interpret, and visualize data in various ways that reveal
relationships, patterns, and trends in the forms of map, reports, and charts (74). The
application of GIS has been used by health care researchers for decades and in recent
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years, it has grown rapidly. GIS can be a useful tool to help understand the spatial
organization of providers, mammography facilities, and its relationship to access and
utilization, breast cancer stage at diagnosis, and mortality. Understanding the
geographical and social connections between providers and the locations of
mammography facilities is important for developing effective healthcare interventions to
reduce breast cancer morbidity and mortality.
Purpose and Specific Aims
The purpose of this dissertation was to examine whether travel distance to the
provider, diagnosing mammography facility, and closest mammography facility are
associated with completion of abnormal mammography follow-up, breast cancer stage at
diagnosis and mortality among women in South Carolina’s National Breast and Cervical
Cancer Early Detection Program (NBCCEDP), Best Chance Network (BCN).
Aim 1: Determine the relationship between geographic proximity to the provider,
diagnosing mammography facility, and closest mammography facility and completion of
abnormal mammography follow-up among women in the Best Chance Network (BCN).
Research Question 1: Are there associations between distance to the provider,
diagnosing mammography facility, closest mammography facility, and completion of
abnormal mammography follow-up among women in the BCN?
Aim 2: Evaluate the role of distance to the provider, diagnosing mammography facility,
closest mammography, and breast cancer stage at diagnosis among women in the BCN.
Research Question 2: Does living further from the provider, diagnosing mammography
facility, and closest mammography increase the risk of having advanced stage of breast
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cancer at diagnosis among women in the BCN? Also, is there a difference by
race/ethnicity?
Aim 3: Evaluate the role of distance to the screening provider, mammography facility,
and mortality among women in the BCN.
Research Question 3: Does living further from the provider and closest mammography
facility increase the risk of breast cancer mortality among women in the BCN? Also, is
there a difference by race/ethnicity?
Significant of Research
Breast cancer is a major contributor to morbidity and mortality among women in
South Carolina and nationally. Among other factors, timely follow-up of an abnormal
mammogram and breast cancer stage at diagnosis contribute largely to breast cancer
morbidity and mortality. This study examined some important predictors, distance to the
provider, diagnosing mammography facility, closest mammography facility, and its
relationship with completion of abnormal mammography follow-up and breast cancer
stage at diagnosis and mortality among low socioeconomic status women in South
Carolina. This study contributes to the understanding of population-level barriers to
abnormal follow-up and breast cancer stage at diagnosis, which may guide policy
development and the development of effective programs to reduce breast cancer
morbidity and mortality. From a recent review of the literature, there has been no study
examining distance to the provider, mammography facilities, and its effect on completion
of abnormal follow-up and breast cancer stage at diagnosis and mortality among women
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in South Carolina. This study adds to the breast cancer disparities research in South
Carolina.
Summary
Among women in the United States, breast cancer is most common cancer and the
second leading cause of death (1). The American Cancer Society estimated over 226,870
women were diagnosed with breast cancer in 2012, and about 18% of them died of the
disease (1). Mammography is the single most effective screening tool for early detection
of breast cancer. Mammography screening for breast cancer reduces mortality from
breast cancer when women receive timely follow-up and appropriate treatment. With all
the benefits of mammography, many women are not up-to-date on screening and not
maintaining annual adherence to screening mammograms (10, 11, 19, 20).
Breast cancer stage at diagnosis is an important factor in survival and mortality.
Studies consistently show that low-income, health insurance status, community poverty,
and racial/ethnic minorities are more likely to be diagnosed with late-stage breast cancer
(53-59); Women with these factors are also less likely to utilize mammography screening
(28-32, 36), less likely to have timely and complete follow-up after an abnormal
mammography screening (39-41, 44), and have poorer survival (51-53). Understanding
the geographical and social connections between providers, mammography utilization,
and the locations of mammography facilities are important for the development of
effective healthcare interventions to reduce breast cancer morbidity and mortality. The
objective of this dissertation was to examine whether travel distance to provider,
diagnosing mammography facility, and closest mammography facility affect completion
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of abnormal mammography follow-up, stage of breast cancer at diagnosis and mortality
among women who have equal access to screening in South Carolina’s Best Chance
Network.
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CHAPTER 2
BACKGROUND & SIGNIFICANCE
This chapter presents a literature review of breast cancer, including Breast Cancer
Incidence and Prevalence, Breast Cancer Risk Factors, Breast Cancer Morbidity and
Mortality, and Breast Cancer Stage at Diagnosis. It follows with Mammography
Screening Recommendations and Utilizations, Abnormal Mammography and Follow-up,
Distance to Mammography Facilities and Breast Cancer Stages at Diagnosis, Breast
Cancer Problem in South Carolina and the Best Chance Network (BCN), Geographic
Information System and Measurement of Access to Health Care, and concludes with a
summary of the chapter.
Breast Cancer Overview
Breast Cancer Incidence and Prevalence
Breast cancer is a type of cancer that starts in the breast where cells divide and
grow without normal control. Among women in the United States, breast cancer is the
most commonly diagnosed cancer and is the second cause of cancer-related mortality (1,
2). About 12.1% of women born today will be diagnosed with breast cancer in their
lifetime (3). The American Cancer Society (ACS) estimated 226,870 women in the
United States were diagnosed with breast cancer and 39,920 died of this cancer in 2012
(1). From 2002-2006, the age-adjusted incidence of breast cancer was 121.8 per 100,000
women and the age-adjusted death rate was 24.5 per 100,000 women per year (4).
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The incidence of breast cancer has been unstable in the last decades; from 19751980, the incidence decreased by 0.5% per year; between 1980-1987, the incidence
increased by 4.0% per year, between 1987-1994, it decreased by 0.1% per year, between
1994-1999, the incidence increased by 1.6% per year, and from 1999-2006, breast cancer
incidence decreased by 2.0% per year (2). The rapid increase of breast cancer incidence
between 1980 and 1987 is most likely attributed to widespread use of mammography
screening and increased detection of breast cancers at an early stage. The decrease from
1999-2006 may reflect reductions in the use of menopausal hormone therapy (MHT),
following the publication of results from the Women’s Health Initiative in 2002, which
found that women using estrogen plus progestin had a 24% increase risk for breast cancer
(5-6).
Breast cancer risk factors
There are several factors that are linked to breast cancer risk. Some factors affect
risk greater than others and some are modifiable, while others are not. Some of the risk
factors reported by the American Cancer Society include age, overweight, use of estrogen
and progestin, physical inactivity, consumption of alcoholic beverages, high breast
density, reproductive factors (long menstrual history, having no child, and having first
child after age 30), family history of breast cancer, inherited genetic mutations in the
breast cancer susceptibility genes BRCA1 and BRCA2, socioeconomic status, and
race/ethnicity (1).
The risk of developing breast cancer increases with age. From birth through age
39, the probability of developing breast cancer is 0.43% (1 in 233 women); 3.75% (1 in
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27 women) for ages 40 to 49; 3.40% (1 in 29 women) for ages 60 to 69; and 6.50% (1 in
15 women) for ages 70 and older (1). Obesity has shown to affect breast cancer risk.
However, the risk is different for pre- and postmenopausal women; before menopause,
obese women have a lower risk of developing breast cancer compared to healthy weight
women. After menopause, being overweight increases the risk of developing breast
cancer by 30 to 60%. (7-10). Postmenopausal hormones use, such as estrogen plus
progestin, increases the risk of developing and dying from breast cancer (5, 6, 11-14).
Beral et al. (14) found that women who use estrogen plus progestin for more than five
years double their risk of developing breast cancer.
Physical activity is an important contributor to health outcome. For breast cancer,
regular activity may help lower the risk (15, 16). In fact, regular exercise can lower breast
cancer risk by about 20% (16). Studies have also shown that physical activity increases
survival among women with breast cancer (17-18). Alcohol consumption is also
associated with higher risk of developing breast cancer. The risk increases with the
amount of alcohol a woman drinks. One large study found that daily consumption of
about 10g (1 drink) was associated with a 9% increase in risk of breast cancer (19).
Increasing the alcohol consumption to ≥30g/day (3+ drinks) was associated with a 43%
increase in risk (19).
Breast density is the proportions of fat and tissue in the breast. Women with high
breast density (greater tissue compared to fat) are at a higher risk of developing breast
cancer (20, 21). One study found that women with 75% or more mammographic density
reading had an odds of 4.7 (95% CI: 3.0-7.4) times the odds of breast cancer compared to
women with less than 10% mammographic density (21).
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Reproductive factors are some of the strongest risk factors for breast cancer
development and accounts for nearly 50% of all breast cancer cases (1). Studies have
shown that reproductive factors, such as long menstrual history, having no child, and
having first child after age 30, are all strong risk factors for breast cancer (22-24).
Women who had their first child after age 30 were 1.27 times likely to develop ductal
breast cancer, 1.79 times for lobular breast cancer, and 1.66 times more likely to develop
tublar breast cancer compared to women who had their first child before age 20 (24).
Inherited genetic mutations in the breast cancer susceptibility genes BRCA1 and BRCA2
can also increase a women’s risk for breast cancer; however, these mutations are rare (1%
of the population) and accounts for 5%-10% of breast cancer cases (1). Family history of
breast cancer increases the risk of developing breast cancer as well. A woman who has
one immediate relative (mother, sister or daughter) with breast cancer increases her risk
by two times; and with more than one immediate relative with the cancer, it increase the
risk to four times higher compared to those with no family history (25, 26).
Women with higher SES (high income and/or high education level) have higher
risk of developing breast cancer (27). There are many factors that may contribute to this
association. Women with higher SES are more likely to have child at a later age, have
fewer children, and also are more likely to use postmenopausal hormones compared to
lower SES women (28-29). On the other hand, women with higher SES are less likely to
die from breast cancer. One study found that women with no education beyond high
school were 1.39 times more likely to die from breast cancer compared to women who
were college graduates (30). Among all race/ethnicity, European American women have
the highest incidence of breast cancer. From 2004-2008, the incidence rate of breast
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cancer among European American was 127.3 per 100,000 women compared to 199.9 per
100,000 women for African American (3). However, African American women are more
likely to die from breast cancer compared to European American women.
Breast Cancer Mortality
In 2012, an estimate of 39,920 women died of breast cancer (1). Though it is the
second leading cause of cancer mortality among women, death rates have steadily
decreased in the past decades (1, 2). Women younger than 50 years of age had a larger
decrease than women older than 50 years of age (3.2% vs. 2.0% per year, respectively)
(1). Early detection and improved treatment have contributed largely to this decrease in
breast cancer and mortality in recent years.
Although overall death rates for breast cancer have declined in the past decades,
the mortality rates differ among racial/ethnic groups and age groups. From 2002-2006,
African American had the highest breast cancer death rates (33.0 per 100,000 women)
compared to European American (23.9 per 100,000 women) (2, 3). Breast cancer deaths
among African American women have also been declining at a slower rate compared to
European American women (31). In the 1980s, death rates were similar for both African
American and European American women; however, since the early 2000s, African
American women had a 39% higher mortality rate compared to European American
women (31). This disparity may be due to breast cancer tumor characteristics seen in
African American. Breast cancers diagnosed in African American women are more likely
to have higher grade, advanced stage, and an aggressive subtype, which all contribute
largely to this mortality disparity (32, 33). Difference in access to and utilization of early
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detection and treatments may also explain why African American women have higher
mortality compared to European American women (34-36).
Age is also an important factor in breast cancer development and mortality.
Women younger than 40 years of age have more aggressive breast cancer subtype, which
is associated with higher mortality compared to older women (37, 38). Premenopausal
women are also more likely to have aggressive subtype and are more likely to die from
breast cancer compared to postmenopausal women (39).
Among women in the United States, the overall 5-year relative survival rate is
~90% (1). Survival rates vary considerably among racial/ethnicity, age, tumor
characteristics, and social factors. The overall 5-year relative survival rate is much lower
for African American women compared to European American women; from 1999-2006,
the 5-year relative survival rate for breast cancer among African American women was
78%, a 13% lower compared to European American women (1). This difference can be
attributed to both later stage at diagnosis and poorer stage-specific survival among
African American women.

From 2003-2007, the median age of mortality from breast

cancer was 68 years of age (3). Majority (57.5%) of breast cancer mortality occurred in
women 65 years old and above (3).
Breast Cancer Stage at Diagnosis
Stage of breast cancer is based on the size of the tumor, whether it has invaded
nearby tissues, and whether it has spread within the breast or to other parts of the body
(40). Breast cancer is categorized into stage 0 through stage IV. Stage 0 is carcinoma in
situ, where the cancer cells have not spread outside of the ducts or lobules. Stage 0 is
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classified into two types: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ
(LCIS). DCIS is the earliest form of cancer where cells are still within a duct and have
not invaded into the surrounding fatty breast tissue. LCIS is when abnormal cells are
found in the lobules of the breast. It is usually not considered a cancer; however, it
increases the risk of developing breast cancer. Stage 1 is the early stage of invasive breast
cancer. Cancer in stage 1 has not spread to surrounding lymph nodes or outside of the
breast. Stage 2 breast cancer is also considered an early stage cancer. Depending on the
tumor characteristics, it divided into two stages: stages 2A and 2B. Stage 3 breast cancer
is a more advanced stage of breast cancer. Stage 3 cancer is divided into three categories:
Stage 3A, stage 3B, and stage 3C. Stage 3A is when the tumor is larger than 5
centimeters in diameter and has spread to the axillary lymph nodes. Stage 3B tumor can
be any size; however, it has spread to the axillary lymph nodes and possibly other lymph
nodes in the body. Stage 3C is the more aggressive type, which is present in adjoining
tissue such as muscles or skin. Stage 4 breast cancer is the most advanced and aggressive
of all stages. In this stage, the cancer has spread to other organs or tissues of the body,
and most often these are the bones, lungs, liver, and brain (40).
The 5-year relative survival rates among women whose breast cancer is diagnosed
while in the early stages have higher survival compared to those diagnosed in later stages.
Among women diagnosed with breast cancer in stage 0, the 5-year relative survival rate
is approximately 93% (41). Stage 1 has a 5-year relative survival rate of 88%, stage 2A
81%, stage 2B 74%, stage IIIA 67%, stage IIIB 41%, stage IIIC 49%, and stage IV breast
cancer has a 5-year relative survival rate of 15% (41). Breast cancer stage at diagnosis is
an important factor in survival and mortality among women.
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Studies consistently show that low-income, health insurance status, community
poverty, and racial/ethnic minorities are more likely to be diagnosed with late-stage
breast cancer and have poorer survival (42-48). Examining seven state registries, Byers et
al. (43) found that among 4,844 women diagnosed with breast cancer, those living in the
lowest SES areas had substantially increased risk of breast cancer mortality (HR= 1.59,
95% CI:1.35-1.87) compared to women not in the lowest SES area. After adjusting for
age and race/ethnicity, the risk of mortality was still significantly higher for women
living in low SES areas (HR=1.33, 95% CI: 1.11-1.58). Clegg et al. (47) found from 11
Surveillance, Epidemiology, and End Results (SEER) cancer registries that lower income
women were statically significantly associated with an increased risk of being diagnosed
with a late-stage breast cancer (p=0.02). The odds for late-stage breast cancer for the two
lowest income categories were 2.3 and 1.8 times higher than those women in the highest
income group, respectively (47). The author also found that non-Hispanic black females
were 2.2 times more likely to be diagnosed with late-stage breast cancer compared to
non-Hispanic white females. Smith et al. (42) examined women participating in the
National Breast and Cervical Cancer Early Detection Program and found that African
American women with late-stage breast cancer at diagnosis and negative ER/PR hormone
receptor were at increased risk of mortality compared to European American women.
Barry and Been (46) conducted a study examining residential characteristics and latestage breast and cervical cancer among women in the SEER registries. They found that
women in three major metropolitan SEER areas (Atlanta, Georgia; Detroit, Michigan;
and San Francisco, California) that resided in economically and socially distressed or
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medically underserved areas (MUAs) were more likely to have late-stage breast cancer at
diagnosis compared to those women who were not in those areas.
Mammography Screening Recommendations and Utilizations
Regularly breast cancer screening is the best way for women to reduce their risk
of dying from breast cancer. In fact, death rates for breast cancer have steadily decreased
in women due to earlier detection, such as mammography, and improved treatments (49). Breast self-examination (BSE), clinical breast exam (CBE), and mammography are
the most widely used methods for breast cancer screening.
Breast self-examination is done by a woman examining her own breasts to detect
for possible lumps, changes in size or shape of the breast, or any abnormality of the
breast. Clinical breast exam is examination by a health care provider, who uses his or her
hands to feel for lumps or other changes in the women’s breast. A mammogram is an xray screening of the breast. Inside tissues of the breast are examined for abnormal
changes. Mammography is the single most effective method of early detection for breast
cancer. It can identify the cancer at an early stage, when treatment is more effective (1,
49). The American Cancer Society screening guidelines recommend that average-risk
women aged 40 and older receive mammography screening on an annual basis; have
clinical breast exam about every 3 years for women in their 20s and 30s and every year
after age 40; and an annual breast self-exam as an option for women starting in their 20s
(1).
Annual mammography with adequate follow-up is estimated to result in
reductions in mortality ranging from 25% to 44% (50-55). Mammography is a highly
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accurate screening tool, but like most medical tests, it does not have perfect sensitivity
and specificity. Generally, reported positive predictive values ranges from 78% to 90%
(1, 56, 57). One drawback of mammography is the false positive results. Elmore et al.
(58) conducted a 10-year retrospective cohort study of breast-cancer screening and found
that over the 10-year period of annual mammogram screenings among 2,400 women, the
chance of having a false positive result was close to 50%.
Despite the benefit of mammography, many women are not up-to-date on
screening (59-61) and, in fact, mammography uses have been declining in the past years
(59, 62-64). About 38%-54% of women do not maintain annual adherence to screening
mammograms (59, 60), and only 49% having received screening when using a biennial
schedule (60). Inadequate screening is associated with late stage breast cancer at
diagnosis (65-68), which contributes largely to survival and mortality.
Hahn et al. (66) found that among 829 women who had no mammograms in the
past 5 years had 1.95 times the risk of developing stage III/IV breast cancer compared to
those who had more than 2 mammograms in the past 5 years. They also found that the
risk was higher for African American women compared to European American women;
African American women had an odds of 3.57 (95% CI=2.26-5.65) of having stage III/IV
compared to European women. In a large prospective cohort of over 1 million women,
Smith-Bindman el al. (68) found that among women who had at least one mammogram
between 1996 and 2002, African American women had higher risk of developing
advanced-stage breast cancer compared to European American women.
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Factors Associated with Mammography Utilization
Factors associated with mammography utilization have been scrutinized in
numerous studies, which includes patients characteristics, socioeconomic status,
insurance status, having a primary health care provider, recommendations for screening
from primary health care providers, lack of transportation/or time and distance, language
barriers, concern about the effects of radiation, and fear of cancer (69-78). A systematic
review of 221 studies by Schueler, Chu and Smith-Bindman (70) found that physician
access barriers were associated with not obtaining mammography. Not having a
physician-recommend mammography and having no primary care provider were found to
be highly predictive factors for not obtaining mammography (OR: 0.16, 95% CI 0.080.33 and OR: 0.47, 95% CI 0.39-0.57, respectively). Barr et al. (74) also concluded that
the number of primary care and gynecology physician visits was strongly associated with
having a subsequent mammogram.
Participation of healthcare facilities in encouraging breast cancer screening can be
an important factor in increasing breast cancer screening. Quinley et al. (77) compared
mammography screenings among women attending health facilities that send annual
mammography reminders to those women who attend health facilities that do not send
reminders. They found that among women who attend facilities that send annual
reminders, 74% of the women received a second mammogram within 18 months
compared to 67% for women who did not receive reminders.
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Abnormal Mammography and Follow-up
Mammogram results are interpreted by radiologists using the American College
of Radiologist Breast Imaging Reporting and Data System (BIRADS TM) categories: 0 –
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven
malignancy” (79). A category of 3, 4, and 5 will require additional diagnostic procedures
to determine the presence or absence of the disease (79). Table 2.1 shows the BIRADSTM
categories and recommendations for the categories.
Table 2.1. Breast Imaging Reporting and Database System (BI-RADSTM)
Category
Meaning
Follow-up
Recommendations
Assessment is Incomplete,
Additional imaging are
0
need additional imaging
needed before a final
evaluation
assessment can be assigned
Negative
Routine annual screening
1
mammography
Probably benign
Routine annual screening
2
mammography
Suspicious
Initial short-term follow up
3
(usually 6-month
examination)
Suspicious abnormality
Biopsy should be
4
considered
Highly suspicious of
Requires biopsy or surgical
5
malignancy
treatment
Known biopsy proven
Definitive therapy
6
malignancy

About 9%-15% of women who receive mammography screening have abnormal
finding that require further testing (80, 81), and approximately 30%-50% never return for
follow-up testing (82, 83). The patient, provider, and system can all contribute to
adequate follow-up. Many factors contributing to inadequate or incomplete follow-up
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have been examined (67, 84-100). These factors include: fear (100), language barrier (82,
89), patient anxiety (85, 89, 93), age (90, 95, 96, 98, 99), cost (90, 93), lack of provider
(100), having case management (88, 91, 92), ethnicity (84, 94-96, 99, 100), education
(86, 96, 98), and income (97, 99).
Though these factors may contribute largely to inadequate to abnormal-follow-up,
there are inconsistent findings. Kerner et al. (87) found no association between SES
variables and timely follow-up on abnormal mammography. One study looking at women
participating in the National Breast and Cervical Cancer Early Detection Program
(NBCCEDP) also found no association between completion of recommended workup and
race (99). Nevertheless, incomplete screening and delayed abnormal follow-up can
negate the potential benefits of identifying breast cancer at an early stage, where
treatment is more effective and cure is more likely. Of the many factors predicting
incomplete and delayed abnormal breast cancer screening follow-up that have been
examined, none has looked at distance to providers, mammography facilities, and
completion of abnormal breast cancer screening follow-up. This present study will
examine this structural and environmental factor that could affect the delay and
completion of abnormal mammography follow-up.
Distance to Mammography Facilities and Breast Cancer Stages at Diagnosis
Studies consistently show that low-income, health insurance status, community
poverty, and racial/ethnic minorities are more likely to be diagnosed with late-stage
breast cancer (42-47). A multilevel approach using spatial methods has been widely used
in breast cancer research to understand some of the disparities in morbidity and mortality.
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A common spatial method that has been examined is spatial accessibility to healthcare
facilities. Accessibility, such as long travel distance, can discourage women to seek
routine preventive care or screening. In the past decades, researchers have explored
geographic proximity to health care or mammography locations and breast cancer stage at
diagnosis (101-109). However, finding has been inconsistent between the studies. There
are six studies that found no association between travel distance to mammography and
breast cancer stage at diagnosis (101-106); however, three studies found that there is an
association (107-109).
Tarvo et al. (101) found no association between breast cancer stages at diagnosis
and patients’ residential address to nearby mammography facilities in Chicago. In their
study, breast cancer stage was categorized as in situ, local, and distant. They calculated
distance using street network from the residential address of each cancer case to each
mammography facility. Instead of using the closest mammography, the authors used the
mean distance to the five closest mammography facilities. While the author tried to
account for choice and constraints that may exist in mammography facility availability to
individuals, they found no association between travel distance and breast cancer stages.
In Virginia, Schroen and Lohr (102) found no relevant relationship between travel
distance to the nearest mammography facility and invasive tumor size. For the outcome,
tumor size was used instead of cancer stages. Distance was calculated from patients’
home location to the nearest mammography facility. After adjusting for age, race,
income, they found no association between travel distance and late stage breast cancer at
diagnosis.
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Wang et al. (103) conducted a similar study in Illinois and found no statistically
significant association between travel time to mammography facilities and stage of breast
cancer at diagnosis. In this study, each cancer case was geocoded to the county and zip
code of residence rather than patients’ residential address. They defined late-stage breast
cancer as diagnosis in stages 2 through 7. Though there was no association between
travel time to mammography facilities and breast cancer stage at diagnosis, they did
found an association between geographical access to primary care physician and latestage breast cancer. The authors noted the no association finding may be due to the
homogeneous population (close proximity) to mammography. The average estimated
travel time was fairly short in Illinois, which may conclude that travel time to
mammography might not be a major issue in the studied population. This study has two
limitations. First, they did not have information on patients’ mammography utilization
and, therefore, could not calculate distance to the actual mammography that the patients
actually use. Second, patients’ residence was geocoded to zip code centroids, which may
not be an accurate estimate of travel time.
Three of the more recent studies from 2010-2011 also found no association
between travel distance and breast cancer stage at diagnosis. A study in 2010 by Celaya
et al. (104) found that among women in New Hampshire, there was no association
between late-stage breast cancer and travel time to the nearest mammography facility. In
this study late stage breast cancer was categorized at stages 2 and 4. They calculated
proximity using both travel time and travel distance using road network and still found no
association. They also found that urban/rural residence was not associated with late stage
breast cancer in their population of study.
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Onega et al. (105) studied this association in Washington in 2011 and also
reported no significant association between travel time and breast cancer stage. Women
with breast cancer stage 1, 2A, and 2B were examined in their study. They examined two
outcomes: stage of breast cancer (stage 2B as late stage) and tumor size (≥2cm as late
stage). They used travel time (in minutes) instead of distance (in miles) like some of the
previous studies. With different outcome and travel distance measurement, they still
found no association between travel distance and breast cancer stage at diagnosis. One
major limitation to this study was that patients were limited only to women with earlystage breast cancer (1, 2A, and 2B).
One of the more recent study by Henry et al. (106) used 10 population-based state
cancer registries (Arkansas, California, Iowa, Idaho, Kentucky, North Carolina, New
Hampshire, New Jersey, New York, and Oregon) to study whether there is an association
between travel distance and breast cancer stage at diagnosis. From the 10 cancer
registries, there were 161,619 women in the study. Tumors that were in situ or localized
stages were considered “early stage” and regional or distant stages were considered “late
stage”. This is the first study to measure both travel distance from the patients’ residence
to the closest mammography facility and to their diagnosing facility. They found no
association to the nearest mammography facility. However, when using distance to the
diagnosing facility, they found weak evidence that shorter travel time was associated with
late stage breast cancer at diagnosis; however, the direction of the effect was the opposite
of what is expected. The odds of having late stage breast cancer at diagnosis was lower
for women with longer travel time to their diagnosing facility. The odds of late stage
breast cancer at diagnosis for women who lived 40-50 minutes from their diagnosing
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facility was 0.83 times the odds for women who lived <10 minutes. The trend was similar
as the distance from the diagnosing facility increased.
The first study to find an association between travel distance and breast cancer
stage at diagnosis was conducted in Los Angeles by Gumpertz et al. (107). In this study,
stage of breast cancer was categorized as “advanced disease” if the stage of breast cancer
at diagnosis is regional with tumor diameter < 10 cm or as distant with any tumor size.
They used Euclidean (straight line) distance from the patients’ census tract centroid to the
nearest mammography facility. Distance was broken down into two categories: 10km vs.
1km. After adjusted for neighborhood characteristics and tumor biology, distance from
the census tract centroid to the nearest mammography facility was a significant predictor
of advanced stage of breast cancer; however, this association was only found for Hispanic
and White women. This study used census tract centroids to calculate the distance to the
mammography facility, which may not be an accurate measurement of travel distance.
They also did not use road network, therefore, distance calculated may be under
estimated.
Another study that found an association between travel distance and breast cancer
stage was done in Kentucky by Huang et al. (108) in 2009. Tumors that were in situ, or
stage 1 or 2 were considered “early stage,” and tumors stage 3 or 4 were considered
“advanced stage.” They calculated travel distances from patients’ zip code centroid to the
nearest mammogram facility along the road network. Adjusting for various
characteristics, they found that women living 15+ miles from the nearest mammography
was 1.48 times more likely to have advanced stage of breast cancer at diagnosis
compared to women who lived less than 15 miles. There are two limitations to this study.
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First, this study assumes that women had access to mammogram centers closest to their
homes, which may not always be true due to other circumstances. The other is using zip
code centroids as patients’ place of residence; this may not accurately measure true
residence, which may affect true distance calculation from home to nearest
mammography facility.
The last and more recent study by Dai (109) in 2010 found that there is an
association between travel distance and late-stage breast cancer at diagnosis in Detroit.
In this study, early stage breast cancer was defined as “in situ” and “localized,” and late
stage was defined as “regional” and “distant.” The author used zip code centroids of
patients’ residence to calculate the distance to the nearest mammography and primary
care facilities. Controlling for socioeconomic factors at ZIP code level, the author found
that women living in areas with greater black segregation and poorer mammography
access significantly increases the risk of late stage breast cancer at diagnosis. Compared
to Wang et a. (103) who found association between primary care access and late-stage
breast cancer, this study found no association between this relationship. Like previous
studies, a limitation of this study is the use of ZIP code of residence at diagnosis and not
using network road to calculate the distance.
All of these studies, except one (106), had no information on patients’
mammography utilization. Using the nearest mammography facility may not represent
patient utilization. A patient may not utilize the nearest facility due to personal and
neighborhood characteristics, such as hours of operation, insurance requirement, and
location to work. Relying on the closest mammography facility may underestimate the
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true travel distance between patients’ residence and actual mammography usage if the
closest facility is not the one being utilized.
When mammographic facilities are not conveniently located, women may not
have regular mammograms, which may result in diagnosis of breast cancer at later stage.
Geographic proximity is an important factor in determining breast cancer stage at
diagnosis; however, studies have found inconsistent association between this relationship.
From the above studies, there were differences and similarity in the methodology used in
examining breast cancer stage and travel distance to mammography facility. Even
though, some studies used the more precise measurement of distance (patients’ residence
at diagnosis and road network), they still found no association between breast cancer
stage at diagnosis and travel distance. Others used zip code centroids to calculate the
distance travel and found association between this relationship. The inconsistent results in
the literature highlight the need for further research to determine whether women living
further from mammography facilities are at an increased risk of having late stage breast
cancer at diagnosis. This dissertation examines this relationship in South Carolina among
women participating in the National Breast and Cervical Cancer Early Detection Program
(NBCCEDP).
Breast Cancer Problem in South Carolina and the Best Chance Network (BCN)
South Carolina is a relatively rural state with approximately 30% African
American (110). The poverty rate in South Carolina from 2008-2009 is about 20%, with
African American having the higher rate compared to European American (35% vs. 13%,
respectively) (110). At close to 18% (111), South Carolina has one of the highest
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proportions of uninsured women in the nation, which is a strong predictor of breast
cancer mortality and morbidity (27, 28, 30, 47). Along with the appalling statistics of the
state, South Carolina has some of the highest cancer statistics in the nation, especially
breast cancer morbidity and mortality (112, 113).
In 2012, the American Cancer Society estimated 3,570 women in the state of
South Carolina were diagnosed with breast cancer and about 660 women died of the
disease (1). Breast cancer is most common cancer diagnosed and is the second largest
cause of cancer deaths among women in South Carolina (112). Statewide, the ageadjusted incidence of breast cancer from 2002-2006 have remained stable at around 119
per 100,000 women (1), with a higher age-adjusted incidence among European American
women compared to African American women (127.6 and 111.3 per 100,000 women,
respectively) (114). The burden of this disease weighs heavily on low income, uninsured
African American (42, 99).
To reduce the disproportionate burden of breast cancer and cervical cancer among
women, the U.S. Congress authorized the National Breast and Cervical Cancer Early
Detection Program (NBCCEDP) in 1990 (115). Since then, the program has established
service delivery and ensures timely and complete diagnostic follow-up and treatment
initiation for underserved women screened through the program.
South Carolina’s NBCCEDP, also known as the Best Chance Network (BCN), is
a network of public and private partnerships with more than 250 health care providers
offering screening and follow-up services to disadvantaged women in the State. South
Carolina has one of the highest proportions of uninsured women in the nation, of which
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majority of these women are eligible to enroll in the program. The majority (60%) of
women in BCN are African American and reside in rural counties (111). The BCN offers
an unique opportunity to explore the relationship between distance to the provider,
mammography facilities, and breast cancer morbidity and mortality among women in
South Carolina.
Geographic Information System and Measurement of Access to Health Care
Geographical Information System (GIS) is a system designed to input, store, edit,
retrieve, analyze, and output geographic data information (116). It allows individuals to
view, understand, question, interpret, and visualize data in various ways that reveal
relationships, patterns, and trends in the forms of map, reports, and charts (117). The
application of GIS has been used by health care researchers for decades and in recent
years, it has grown rapidly. The capability of GIS has made it possible for health care
researchers to spatially understand health issues such as health care distribution, access
and utilization, disease risks related to environmental exposures, and morbidity and
mortality, social demographic data, and morbidity and mortality (118-120).
In terms of health care accessibility, there are several measurements of
accessibility. Distance to the nearest provider is one of the most commonly used
measures of spatial accessibility in health care research. This is done by calculating the
distance between patients’ residence or centroid of a ZIP code and census tract to the
nearest health care provider. There are three commonly used methods to measure this
distance: i) Euclidean or straight line distance; ii) travel distance along a road network;
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and iii) travel time along a road network (both taking account of traffic and not taking
account of traffic) (121, 122).
The Euclidean distance measures straight-line distance from two points of
interests. These points can be points, lines or polygons (121). This method has its
advantage and disadvantage. The key advantage of using this method is that it is easy to
calculate. The disadvantage is that it does not take into account the transportation
network or topography of an area that might lengthen the distance traveled from one
point to the other.
Travel distance along a road network or street distance is based on the network of
streets that would be traveled from one location to another (122). This method offers a
more accurate measure of the actual path between two points; therefore, it provides a
more realistic measure of actual distance traveled than the Euclidean method. Travel time
or driving time is similar to travel distance between two points, but is based on driving
time on a road network. This process utilizes information about road length and average
travel speeds along street segments (122).
In geographical access to health services, travel distance and travel time along the
road network are recognized as the more appropriate measures of the travel effort
actually experiences than the Eulicudean distance, which does not take into account of
physical barriers (e.g. rivers or hills) and patchy road network (123). In fact, Shalid et al.
(124) found that Euclidean distance tends to underestimate road distance and travel time
when measuring the distance between patients’ residence and health care facility.
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Using GIS to estimate actual travel time by patients has shown good correlations.
Haynes et al. (125) conducted a validation study comparing GIS estimates of travel
distance with the actual times reported by 475 cancer patients who had travelled by car to
attend clinics. The correlation between reported times and estimated travel times was
0.87, which is a moderately strong association. They also found that straight line distance
and reported travel was moderately strong correlation (r=0.85, p<0.001).
GIS can be a useful tool to help understand the spatial organization of
mammography facilities and its relationship to access and utilization of mammography,
breast cancer stage at diagnosis, and mortality. Understanding the geographical and social
connections between mammography utilization and the locations of mammography
facilities are important for developing effective healthcare interventions to reduce breast
cancer morbidity and mortality.
Summary
Among women in the United States, breast cancer is the most commonly
diagnosed cancer and is the second cause of cancer-related mortality. In 2012, 226,870
women in the United States were diagnosed with breast cancer and 39,920 died as a result
of this cancer. From 1999 to 2006, breast cancer rates had decreased by 2.0% per year,
which may be due to the reduction in use of menopausal hormone therapy. There are
several factors that are linked to breast cancer risk. Some factors affect risk greater than
others and some are modifiable, while others are not.
Comparing to European American women, African American women had the
highest breast cancer death rates (33.0 per 100,000 vs. 23.9 per 100,000). This disparity
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may due to the breast cancer characteristics diagnosed among African American women.
Breast cancer stage at diagnosis is an important factor in survival and mortality. The 5year relative survival rates among women whose breast cancer is diagnosed while in the
early stages have higher survival compared to those diagnosed in later stages. Regular
breast cancer screening is the best way for women to reduce their risk of dying from
breast cancer. In fact, annual mammography with adequate follow-up is estimated to
result in reductions in mortality ranging from 25% to 44%.
Mammogram results are interpreted by radiologists using the American College
of Radiologist Breast Imaging Reporting and Data System (BIRADS TM). A category of 3,
4, and 5 will require additional diagnostic procedures to determine the presence or
absence of the disease. About 9%-15% of women who receive mammography screening
have abnormal finding that require further testing. The patient, provider, and system can
all contribute to adequate follow-up.
Travel barriers, such as long travel distance, can discourage women to seek
routine preventive care or screening. A common measurement of spatial accessibility is
travel distance or travel time from a residential place to the closest facility. Geographic
proximity may be an important factor in determining breast cancer stage at diagnosis;
however, studies have found inconsistent association between this relationship. The
inconsistent results in the literature highlight the need for further research.
South Carolina has some of the highest cancer statistics in the nation, especially
breast cancer morbidity and mortality. South Carolina also has one of the highest
proportions of uninsured women in the nation. South Carolina’s NBCCEDP, also known
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as the Best Chance Network (BCN), is a network of public and private partnerships with
health care providers offering screening and follow-up services to disadvantaged women
in the State. The BCN offers an unique opportunity to explore the relationship between
distance to provider, mammography facilities, and breast cancer morbidity and mortality
among women in South Carolina.
There are three commonly used methods to measure travel distance between two
points of interest: i) Euclidean or straight line distance; ii) travel distance along a road
network; and iii) travel time along a road network. GIS can be a useful tool to help
understand the spatial organization of mammography facilities and its relationship to
access and utilization of mammography, breast cancer stage at diagnosis, and mortality.
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CHAPTER 3
METHODOLOGY

This chapter describes the data source and methods that was used to conduct the
study. The chapter begins with the study design and then goes on to describing the data
source, participant inclusion criteria, outcome of interest, main exposure and covariates,
and data analysis for each of the specific aims. Lastly, it ends with a summary of the
chapter.
Study Design
This study was a retrospective cohort study that covers a period of 14 years
between 1996 and 2009. The purpose was to investigate travel distances (to the screening
provider, diagnosing mammography facility, and closest mammography facility) and
completion of abnormal mammography follow-up, breast cancer stage at diagnosis, and
mortality among women participating in the Best Chance Network. The present study
used secondary data, collected for billing and national surveillance purposes, and no
primary data collection among participants was required. Of note, all analytic work
requiring the use of protected health information (e.g. distance calculation) was
completed on-site at the South Carolina’s Department of Health and Environmental
Control (SC DHEC). Only a de-identified dataset was released from DHEC for analysis.
Neither the PI nor any other investigators were able to view identifiable or restricted data.
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Data Source and Data Analysis for Aims 1, 2 and 3
Aim 1: Determine the relationship between geographic proximity to the screening
provider, closest mammography facility, diagnosing mammography facility, and
completion of abnormal mammography follow-up among women in the Best Chance
Network (BCN).
Research Question 1: Are there associations between travel distance to the screening
provider, closest mammography facility, diagnosing mammography facility, and
completion of abnormal mammography follow-up among women in the BCN?
For aim 1, the dataset source came from the South Carolina Best Chance
Network. The program is part of the National Breast and Cervical Cancer Early Detection
Program (NBCCEDP), which began in 1990 (1). It is a network of public and private
partnerships with more than 250 health care providers offering service delivery and
ensures timely and complete diagnostic follow-up and treatment initiation for
underserved women screened through the program. Over the past five years (2005-2010)
the program had served over 36,500 women in the State (2).
Mammogram results are interpreted by radiologists using the American College
of Radiologist Breast Imaging Reporting and Data System (BIRADSTM) categories: 0 –
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven
malignancy” (3). A category of 4 and 5 will require additional diagnostic procedures to
determine the presence or absence of the disease. All participants with abnormal
mammography are provided with case management services, which work with the

54

participant to help her receive follow-up diagnostic services within 60 days. In the last
five years (July 2005-June 2010), the Best Chance Network performed over 40,100
mammography screening and 5,241 of them were abnormal or incomplete results (2).
Inclusion Criteria for Aim 1
Women included in the dataset include:


Enrolled in BCN between 1996 and 2009



Having an abnormal mammogram, a BIRADS category of 4 or 5



Having diagnostic work-up planned for breast cancer



Having status and date of final diagnosis record



Known screening provider



Residence address is not a PO Box address

Aim 1 Outcome of Interest
The dependent variable for aim 1 was time-to-resolution or completion of
abnormal mammogram follow-up. The measure of time was the number of days between
the first mammogram and the date that the follow-up status was finalized (work-up
completed, refused, or lost-to-follow up). A completed work-up is designated when the
diagnostic testing is complete and a final diagnosis has been made (benign or malignant
breast cancer). Refused work-up indicates a woman had her diagnostic work-up
performed by another provider. A loss-to-follow up status indicates that the woman died,
moved before her work-up started, or BCN could not make contact with the patient.
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Aim 1 Main Exposure and Covariates
There were three main exposure variables for aim 1: There were three main
exposure variables of interest: travel distance to the screening provider, travel distance to
the diagnosing mammogram facility, and travel distance to the nearest mammography
facility. All three distance calculations were calculated along a road network from
patients’ residence to the facility of interest. Confounders and effect modifiers included
age, race, previous mammogram, yearly family income, and insurance status at time of
visit with the BCN.
Data Analysis
GIS Approach
Mammography facilities, screening providers, and patients’ residence were
geocoded to the exact street address of location. The geocoded addresses (latitudes and
longitudes) were used to calculate the three distances (in miles) between residence and
the diagnosing mammography facility, screening provider, and the nearest
mammography facility. All geocoding of addresses was done using ArcGIS (ESRI,
Redlands, CA). Distance calculations were performed by using the Network Analyst tool
function in ArcGIS. Once the distance variables were calculated, a de-identified dataset
was exported to SAS for analyses. All GIS analyses of this study were done on-site at SC
DHEC.
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Statistical Methods
Descriptive statistics were calculated for all characteristic variables. Chi-square
test and t-test were used to examine the bivariate associations between demographic and
race variables. The median days and distances from the abnormal mammogram to
diagnostic resolution were assessed with Kaplan-Meier survival method. Wilcoxon test of
equality over strata was used to test for statistical significant between the distances.
Cox proportional hazard modeling was used to assess the relationship between
work-up completion and travel distance to the screening provider and mammography
facility. Women whose final status was recorded as refused or loss-to-follow up were
considered censored observations. The proportional hazards assumption was examined
through the logarithm of negative logarithm of survival probability with logarithm of
time and the Schoenfeld residuals were further evaluated to confirm that there were no
violations of the assumption. All analyses were performed using SAS version 9.3 (Cary,
NC). A two-sided alpha level of 0.05 was used to determine significant for all tests.
Aim 2: 1) Investigate whether travel distance to the screening provider and
mammography facility are associated with breast cancer stage at diagnosis among
women participating in South Carolina’s BCN, 2) examine whether there are racial
disparities in the distribution of breast cancer stage at diagnosis among BCN
participants, and 3) examine whether there are any differences in the distribution of
breast cancer stage at diagnosis among BCN participants and non-BCN
participants?
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Research Question 2: Does living further from the screening provider, diagnosing
mammography facility, and diagnosing mammography facility increase the risk of
being diagnosed with a more advanced stage of breast cancer at diagnosis among
women in the BCN? Also, is there a difference by race/ethnicity? Are there
significant differences in the distribution of breast cancer stage at diagnosis among
BCN and non-BCN women in the State of South Carolina?
The South Carolina Central Cancer Registry is a population-based data system
that collects cancer statistics in the state of South Carolina. From the last audit, the
registry has a completeness rate of 96.9% and an accuracy rate of 96.4%, both of which
exceeded the national standard of 95%. SCCCR also maintains a “Gold Certification”
from the North American Association of Central Cancer Registries (NAACCR) (4).
Thus, the data are of high quality, validity, and completeness. For aim 2, the dataset
source came from both the BCN and SCCCR. SCCCR did the data linkage to the BCN
data. This data linkage allowed the identification of BCN breast cancer cases in SCCCR,
the screening providers, and the diagnosing mammography facility. To compare breast
cancer stage at diagnosis between BCN and non-BCN women, we identified non-BCN
women with breast cancer from SCCCR between 1996 and 2009.
Inclusion Criteria for Aim 2
Women included in the dataset include:


Is a first primary breast cancer case in SCCCR between 1996 and 2009



Enrolled in BCN between 1996 and 2009



Known breast cancer stage at diagnosis
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Known screening provider



Residence address is not a PO Box address

Aim 2 Outcome of Interest
The outcome of interest was breast cancer stage at diagnosis. Using the
Surveillance Epidemiology and End Results (SEER) Summary Staging guide, breast
cancer stages were dichotomized into ‘early stage’ and ‘late stage’; In situ and localized
(confined to primary site) stages were considered ‘early stage’ and regional (spread to
regional lymph nodes) or distant (cancer has metastasized) stages were categorized as
‘late stage’.
Aim 2 Main Exposure and Covariates
As with aim 1, there were three main exposures: distance travel to the screening
provider, distance travel to the diagnosing mammography facility, and distance travel to
the nearest mammography facility. Confounders and effect modifiers included age, race,
income at time of enrollment, insurance status at time visit with the BCN, and marital
status. Race was categorized as EA and AA. Income at time of enrollment was
categorized into three groups: <$10000, $10000-$19999, and >$20000. Health insurance
status was categorized as Yes and No. Marital status was categorized into five groups:
single, married, separated/divorced, widowed, and unknown.
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Data Analysis
GIS Approach and Statistics Methods
As with aim one, distance calculations and goecoding were done on-site at SC
DHEC. A de-identified dataset was exported to SAS for analyses. Descriptive statistics
were performed for all characteristic variables. Chi-square test and t-test were used to test
for differences between demographic and race variables. Chi-square was also used to
compare breast cancer stage at diagnosis between BCN and non-BCN women.
Multivariable logistic regression was used to assess the association between travel
distance (to the screening provider, diagnosing mammography facility, and closest
mammography facility) and stage of breast cancer at diagnosis. To assess whether travel
distance was influenced by race, an interaction term was created between travel distance
and race in each of the model (travel distance to screening provider-race, travel distance
to diagnosing mammography facility-race, and travel distance to closest mammography
facility-race). All distances to the health facilities were broken into < 5 miles, 5-<10
miles, 10-<15 miles, and 15+ miles for statistical analysis. All analyses were performed
using SAS version 9.3 (Cary, NC). A two-sided alpha level of 0.05 was used to determine
significance for all tests.
Aim 3: Evaluate the role of distance to the screening provider, nearest
mammography facility, and mortality among women in the BCN.
Research Question 3: Does living further from the screening provider and closest
mammography facility increase the risk of breast cancer mortality? Also, is there a
difference by race/ethnicity?
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For aim 3, the dataset source was the same dataset as in aim 2 (linkage between
SCCCR and BCN).
Inclusion Criteria for Aim 3
Women included in the dataset include:


Is a first primary breast cancer case in SCCCR between 1996 and 2009



Known year of diagnosis



Known screening provider



Enrolled in BCN between 1996 and 2009



Residence address is not a PO Box address

Aim 3 Outcome of Interest
The outcome of interest was breast cancer-specific and all-cause mortality. To
determine breast cancer-specific mortality, we looked at the “Sequence Number” and the
“Cause of Death” from the cancer registry data. If the “Sequence Number” was “00”,
meaning that the subject had one malignant primary in her lifetime, and the “Cause of
Death” was “Cancer”, then the death was related to breast cancer. If the subject died of
any cause of death, including breast cancer, then the death was considered all-cause
mortality.
Aim 3 Main Exposure and Covariates
For aim 3, there were three main exposures: distance travel to the screening
provider, distance travel to the nearest mammography facility, and distance travel to the
diagnosing mammography facility. Patients’ characteristics were obtained from the BCN
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and SCCCR, which included age, race, breast cancer stage, estrogen receptor status,
marital status, health insurance, income, and first course of treatment. Breast cancer stage
at diagnosis was categorized as in-situ, localized, regional, and distant. Estrogen receptor
(ER) status was categorized as positive, negative, and borderline. Income at time of
enrollment was categorized into three groups: <$10000, $10000-$19999, and >$20000.
Health insurance status was categorized as Yes or No. Marital status was categorized into
married or not married. Cancer treatments were categorized as surgery, radiation,
chemotherapy, hormonal therapy, and none.
Data Analysis
GIS Approach and Statistics Methods
As with aims 1 and 2, geocoding and distance calculations were done on-site at
SC DHEC and only a de-identified dataset was given to the researcher for analyses.
Descriptive statistics were calculated for all characteristics variables. Chi-square tests and
t-tests were used to examine the associations between characteristics variables and race.
Survival probabilities for breast cancer-specific and all-cause mortality were examined
using Kaplan-Meier survival method. Cox proportional hazard modeling was used to
assess the relationship between mortality and travel distance to the screening referral
provider, diagnosing mammography facility, and closest mammography facility. To
assess whether travel distance was influenced by race, we created an interaction term
between travel distance and race in each of the Cox proportional hazard model (travel
distance to screening provider-race, travel distance to diagnosing mammography facility-
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race, and travel distance to closest mammography facility-race). Due to low sample size,
all distances were categorized into <10 miles and 10+ miles for analysis.
Individuals not found to be deceased at the end of the time period, December 31,
2009, were considered to be alive at the time of censoring. For breast cancer specific
mortality, non-cancer cause of death and cancer death other than breast cancer were also
considered censored. The proportional hazards assumption was examined through the
logarithm of negative logarithm of survival probability with logarithm of time and the
Schoenfeld residuals were further evaluated to confirm that there were no violations of
the assumption. Missing data were excluded from analyses. All analyses were done using
SAS statistical software version 9.3 (Cary, NC). All statistical tests were 2-sided with a
P-value of ≤ 0.05 used to determine statistical significance.
Summary
This study used 14 years of data (1996-2009) to investigate the relationship
between three types of travel distances (to the screening provider, diagnosing
mammography facility, and closest mammography) and completion of abnormal
mammography follow-up, breast cancer stage at diagnosis, and mortality among women
participating in South Carolina’s Best Chance Network. Data source for aim one came
from BCN and for aims two and three, the data source came from a linkage between
SCCCR and BCN. Geocoding and distance calculations were performed on-site at the SC
DHEC. Only a de-identified dataset was released from DHEC for analyses. All data
analyses were performed using SAS v. 9.3.
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Abstract
Introduction: Breast cancer is the most common cancer diagnosed and is the second
leading cause of cancer deaths among women in South Carolina. Annual mammography,
with timely and complete follow-up of abnormal mammogram, improves breast cancer
prognosis and survival. Though many studies have examined factors in predicting
incomplete and delay in abnormal mammogram follow-up, none has used geospatial
methods to examine these factors. Consequently, the purpose of this study was to
examine the relationship between travel distance to the screening provider,
mammography facility, and completion of abnormal mammogram follow-up among
disadvantaged women in South Carolina. Methods: Women participating in South
Carolina’s Best Chance Network between 1996 and 2009 with abnormal mammogram
(BI-RADS category of 4 or 5) were included in the study. Racial differences in
characteristics and completion of abnormal mammogram follow-up were tested using
chi-square and t-tests. Kaplan-Meier survival method was used to compute time to
completion of abnormal mammogram follow-up and Cox proportional hazard modeling
was used to assess the relationship between work-up completion and travel distance to
screening provider and mammography facility. Results: Among 1,388 women with
mammography abnormalities, more than 95% achieved completion in follow-up. There
was no significant association between race and overall completion of abnormal
mammogram work-up. However, there was significant difference in time to completion
of abnormal mammogram work-up and race; African American women had longer time
to completion compared to European American women. Accounting for race, age,
previous mammograms, income, and insurance status, women who lived closest to their
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diagnosing mammography facility were more likely to complete their work-up compared
to those who lived the farthest (HR=1.41; 95% CI=1.00-1.80). Conclusion: There is no
racial disparity in the overall completion of abnormal mammogram follow-up among
women in the Best Chance Network. However, distance to the diagnosing mammography
facility plays a role on the completion of abnormal mammogram work-up and days to
completion of the work-up, which was longer for African American women.
Introduction
Breast cancer is the most commonly diagnosed cancer and is the second cause of
cancer-related mortality among women in the United States (1). Mammography is the
single most effective method of early detection of breast cancer; it can identify the cancer
at an early stage, when treatment is more effective (2). The American Cancer Society
screening guidelines recommend that average-risk women aged 40 and older receive
mammography screening on an annual basis (1). Annual mammography with adequate
follow-up is estimated to result in reductions in mortality ranging from 25% to 44% (37). Despite the benefit of mammography, many women are not up-to-date on screening
(8-10) and about 38%-54% do not maintain annual adherence to screening mammograms
(8, 9). Inadequate screening and follow-up are associated with late stage breast cancer at
diagnosis (10-14), which lead to poor survival.
About 9%-15% of women who receive mammography screening have an
abnormal finding that require further testing (15, 16), and approximately 30%-50% will
delay follow-up testing (17, 18). Women who delay follow-up testing increase the risk of
having larger tumor size, late-stage breast cancer at diagnosis, and poorer prognosis.
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Factors contributing to inadequate or incomplete abnormal mammogram follow-up
include: fear (19), language barrier (20), race/ethnicity (21-25), lack of provider (25),
income level (24, 26), and education (27).
South Carolina is a relatively rural state with approximately 30% African
American representation (28). The poverty rate in South Carolina from 2008-2009 is
about 20%, with African Americans having a higher rate compared to European
Americans (35% vs. 13%, respectively) (28). At close to 18% (29), South Carolina has
one of the highest proportions of uninsured women in the nation. Breast cancer is the 3rd
most common cancer diagnosed and is the second leading cause of cancer deaths among
women in South Carolina (30).
To reduce the disproportionate burden of breast cancer and ensure adequate
follow-up from abnormal mammograms among disadvantaged women in South Carolina,
the Best Chance Network (BCN), which is the state program of the National Breast and
Cervical Cancer Early Detection Program (NBCCEDP) was established in 1991. The
program has established service delivery and ensures timely and complete diagnostic
follow-up and treatment initiation for underserved women screened through the program.
Though many studies have examined factors in predicting incomplete and delay in
abnormal mammogram follow-up (19-27), none have used geospatial methods to
examine factors related to distance to screening facilities. The purpose of this study was
to examine the relationship between travel distance to the screening provider, diagnosing
mammography facility, closest mammography facility, and completion of abnormal
mammogram follow-up among women participating in the Best Chance Network.
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Methods
Study Setting/Participants
Study participants were women from the Best Chance Network of South Carolina.
The program provides free mammograms, clinical breast exams, Pap tests, pelvic exams,
diagnostic procedures, case management, community education on breast/cervical cancer
and early detection for underserved women aged 47-64 years, who are at or below 200%
of the Federal trade poverty level, and those who lack insurance or have insurance that
only covers hospital care. BCN is a network that consists of public and private
partnerships between federally-funded primary care centers, private physicians,
laboratories, university sponsored clinics, free clinics, regional medical centers, and
radiology facilities. In the last five years (January 2007-December 2011), the BCN has
performed 24,917 mammograms to eligible women in the state (31). .
Mammogram results are interpreted by radiologists using the American College
of Radiologist Breast Imaging Reporting and Data System (BIRADS TM) categories: 0 –
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven
malignancy” (32). A category of 4 and 5 requires additional diagnostic procedures to
determine the presence or absence of the disease. All participants with abnormal
mammography are provided with case management services, which work with the
participant to help her receive follow-up diagnostic services within 60 days.
Subjects were included in the analyses if they were enrolled in BCN between
1996 and 2009 and had an abnormal mammogram BI-RADS reading (BI-RADS category
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of 4 or 5). Only women with race/ethnicity categorized as African American (AA) and
European American (EA) were included in the sample because other individual racial or
ethnic groups (n=31) did not have sufficient numbers to make meaningful contributions
to the analysis. A total of 1,392 BCN participants were obtained from BCN.
The study was approved by the South Carolina’s Department of Health and
Environmental Control (SC-DHEC) and was exempted from approval from the
Institutional Review Board of the University of South Carolina Office of Research.
Measures
The outcome of interest was time-to-resolution or completion of abnormal
mammogram follow-up. The measure of time was the number of days between the first
mammogram and the date that the follow-up status was finalized (work-up completed,
refused, or lost-to-follow up). A completed work-up is designated when the diagnostic
testing is complete and a final diagnosis has been made (benign or malignant breast
cancer). Refused work-up indicates a woman had her diagnostic work-up performed by
another provider. A loss-to-follow up status indicates that the woman died, moved before
her work-up started, or BCN could not make contact with the patient.
There were three main exposure variables of interest: travel distance to the
screening provider, travel distance to the diagnosing mammogram facility, and travel
distance to the nearest mammography facility. The travel distances were calculated in
miles and along the road network based on point location of residence to the facilities
using ArcGIS 9.3 (Redland, CA) Network Analyst. Geocoding of residence and facilities
were done using the Method and Tiers method (33) developed by the SC-DHEC.
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Patients’ addresses, screening providers’ addresses, and diagnosing mammography
facilities’ addresses were obtained from BCN. The closest mammography facilities were
identified from a regularly updated list of Food and Drug Administration (FDA)
accredited facilities (34). Of the 1,392 subjects, we excluded 4 subjects because they
were out of state. We also excluded all patients and screening providers with missing
addresses, addresses that were PO Boxes and those that were matched to the 5-digit zip
code only. There were 1,073 subjects left with matchable addresses. There were 218
screening providers; however, we were able to geocode only 137 facilities due to missing
addresses and PO Boxes. There were 500 patients with a diagnosing mammography
facility designated. Due to change in data collection, a portion of the records only
captured the provider where the initial referral or screening mammography was
performed. Thus, we were unable to perform geospatial analyses using diagnosing
facility for these individuals. There were a total of 111 certified mammography facilities,
identified from the FDA list, in South Carolina that were used as the closest
mammography facilities. All distances to the screening provider, diagnosing
mammography facilities, and closest mammography facilities were broken into < 5 miles,
5-<10 miles, 10-<15 miles, and 15 + miles. Demographic characteristics obtained from
BCN for analyses included age, race, previous mammogram, yearly family income, and
insurance status at time of visit with the BCN.
Statistical Analysis
Descriptive statistics were calculated for all characteristic variables. Chi-square
test and t-test were used to examine the bivariate associations between demographic and
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race variables. The median days and distances from the abnormal mammogram to
diagnostic resolution were assessed with Kaplan-Meier survival method. Wilcoxon test of
equality over strata was used to test for statistical significant between the distances.
Cox proportional hazard modeling was used to assess the relationship between
work-up completion and travel distance to the screening provider and mammography
facility. Women whose final status was recorded as refused or loss-to-follow up were
considered censored observations. The proportional hazards assumption was examined
through the logarithm of negative logarithm of survival probability with logarithm of
time and the Schoenfeld residuals were further evaluated to confirm that there were no
violations of the assumption. All analyses were performed using SAS version 9.3 (Cary,
NC). A two-sided alpha level of 0.05 was used to determine significant for all tests.
Results
A total of 1,073 women were identified through the BCN. The mean age for AA
and EA women was 54.4 (SD=7.01) and 53.8 (SD=7.79), respectively. There was no
statistically significant difference in the mean age between the two race groups (p=0.15).
EA women had higher income than AA women (p<0.01). There was statistically
significant difference for travel distance to the screening provider among AA and EA
women, with EA women having longer travel distance (p<0.01). For both groups of
women, more than 95% had completed follow-up of abnormal mammogram. There was
no statistically significant difference in insurance status, previous mammograms, and BIRADs reading among the groups of women. The study population characteristics are
displayed in Table 4.1.
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The median day to resolution with travel distances are displayed in Table 4.2. The
median day to resolution for travel distance to the screening provider, diagnosing
mammography facility, and closest mammography facility were within 3 days of each
other (22 days, 23 days, and 25 days, respectively). There was no significant difference
between the travel distance to the screening provider and time to resolution. However,
there was significant difference between travel distance to the diagnosing mammography
facility and time to resolution. Women who lived farther from their diagnosing
mammography facility had longer median day to resolution. Figures 4.1-4.3 present the
estimated Kaplan Meier survival curves for travel distance to the health facilities and
time to resolution.
The median days to resolution, stratified by race, are displayed in Table 4.3. For
travel distance to the screening provider, diagnosing mammography facility, and closest
mammography facility, AA women had significantly longer days to resolution compared
to EA women. The largest difference in time to resolution was in travel distance to the
diagnosing mammography facility (28 days for AA women vs. 22 days for EA women).
Figures 4.4-4.6 present the estimated Kaplan Meier survival curves for travel distance to
the health facilities and time to resolution, by race.
Table 4.4 presents the Cox proportional hazard analysis by travel distance to each
of the facilities. Accounting for race, age, previous mammograms, income, and insurance
status, women who lived closest (< 5 miles) to the diagnosing mammography facility
were more likely to complete their work-up compared to those who lived the farthest (15
+ miles) (HR=1.41; 95% CI=1.00-1.80). Though the interaction between travel distance
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and race was not statistically significant, we further analyzed by race because it was
integral to our post-hoc hypothesis. When stratified by race, AA women who lived the
closest to their diagnosing mammography facility were 1.39 times more likely to
complete the recommended work-up compared to AA women who lived the farthest from
their diagnosing mammography (Table 4.5).
Discussion
To our knowledge this is the first study to use geospatial method to examined
travel distance and completion of abnormal mammography follow-up among a
population of women with homogeneous socioeconomic status. In this analysis of women
participating in South Carolina’s Best Chance Network, we found that geographical
location of the health facility plays a role in the completion of work-up following an
abnormal mammographic finding. Women who lived the closest to their diagnosing
mammography facility were more likely to have a completed abnormal mammogram
follow-up compared to those who lived the farthest. Similar to other studies, we found
race was not significantly associated with overall completion of mammographic work-up
(22, 24, 35-36). However, in all travel distances, AA women had longer days to
completion of abnormal mammogram work-up compared to EA women. Among travel
distance to the diagnosing and closest mammography facilities, women who lived the
farthest had longer median days to resolution compared to those who lived the closest.
We performed a sensitivity analysis using travel distance to the diagnosing
mammography and compared with travel distance to the closet mammography facility.
Interestingly, we observed no association between completion of abnormal mammogram
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follow-up and travel distance to the closest mammography facility, but we did observe an
association with travel distance to the diagnosing mammography facility. Women were
more likely to have their abnormal mammogram follow-up completed if they were living
closest to their diagnosing mammography facility. There may be reasons why we see this
unparalleled result. As of 2011, there were 111 certified mammography facilities
(excluding mobile facilities) in South Carolina. We used this updated list of certified
mammography facilities to calculate distance to the closest mammography facility.
Several of these facilities may have been added in recent years and calculating the
distance between these facilities and the patient’s residence may not be the actual closest
mammography facility utilized. By using this list, we are assuming that women received
service at a facility closest to home and that all facilities were in existence at the
beginning of the study (1996). Selection of a facility for service depends on many criteria
and may not always be the closest to home. Hence, inaccuracy of travel distance to the
closest mammography center can occur. This sensitivity analysis showed that by using
the closest mammography facility instead of the actual utilized mammography facility,
we may bias our findings toward to null.
There are several limitations to this investigation that are worth noting. First, the
BCN program collects minimal data elements; therefore, we did not have information on
the patient-provider relationship, or patients’ behaviors and beliefs about breast cancer
screening. This information would be useful in determining the reasons for some of our
findings. Misclassification for the variable ‘status of mammogram at final diagnosis’ can
bias our finding. When grouping ‘refused’ and ‘loss to follow-up’ into incomplete workup, we may have introduced misclassification bias if the factors associated with them are
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different from each other. Nevertheless, our analyses (data not shown) showed that there
were no significant differences between the mean travel distance between those in the
‘refused’ and ‘loss to follow-up’ groups. Exclusion of women for various reasons can
also bias our findings. In this investigation, 315 women were excluded due to PO Box
addresses or not geocodeable to the exact street level. If the characteristics of these
women differ from those with geocodeable addresses, our results may be biased. We
found no significant differences between insurance status, BI-RADS reading, and the
status of mammography at final diagnosis among the geocodeable and non-geocodeable
groups; hence, excluding women with non-geocodeable addresses is unlikely to bias our
estimates.
Our main exposure was travel distance. Though women in the study were
geocoded to the exact street address, the geocoded address may not be the actual location
of residence. This can happen due to new developments, rural areas or streets that are not
captured by the geocoding map. Therefore, when calculating the distance from residence
to the providers and mammography facilities, we may be under or over-estimating the
true distance of travel. How much this biases our findings is unknown.
Though we used road network to measure the distance from patient’s residence to
the screening provider and mammography facility, we had no information on other
factors that can affect utilization such as car ownership or reliability of public
transportation. The type of transportation a patient uses can affect whether a patient will
go to the health center or not. It has been shown that transportation is an important factor
and is associated with mammography receipt (37).
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The major strength of this analysis is that we derived travel distance from the
exact street address of a patient’s residence to the screening provider and mammography
facility. This method gives us a more precise measurement of travel distance compared to
other method that has been used in computing travel distance, which uses the five-zip
code centroid.
In addition, we were able to compute distance to the diagnosing mammography
facility. Healthcare can sometime be a choice and patient may not always utilize the
closest health facility due to various reasons. By using the actual diagnosing
mammography facility to compute the distance from the patient’s residence, we have a
good estimate of the actual travel distance. From our analysis, we found an association
between travel distance to diagnosing mammography facility and completion of abnormal
mammogram follow-up, but not for the closest mammography facility.
In conclusion, we found no racial disparity in the overall completion of abnormal
mammogram work-up among AA and EA women participating in the BCN program and
approximately 86% of the women had their work-up completed within 60 days. This
suggests that the program is meeting established program standards of timeliness and
completeness of follow-up for women with abnormal mammographic finding. However,
we did found that geographical location of the diagnosing mammography facility plays a
role in the days to completion of work-up. Women living closest to their diagnosing
mammography facility were more likely to complete the work-up and have shorter days
to completion compared to those who lived the farthest. In addition, we found evidence
of racial disparity in the time to completion of abnormal mammogram work-up; AA
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women had longer days to completion compared with EA women. These finding reveals
that geographic accessibility to mammography facility may have an impact on
completion of abnormal mammogram work-up and days to completion of the work-up.
Intervention strategies and additional support to the BCN program to expand services
should be investigated to reduce the disparity in days to completion of abnormal
mammographic finding among racial ethnic groups. Further research that examines
factors which affect geographic access, such as ownership of reliable transportation and
access to public transportation, may further our understanding.
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Table 4.1. Demographic Characteristics of the Study Population, by Race*
Black (n=591)
White (n=482)
Characteristics
n (%)
n (%) p-value
n (mean±SD)
n (mean±SD)
Age
<40 years
7 (1.2%)
13 (2.7%)
0.19
40-49 years
149 (25.2%)
135 (28.0%)
50-64 years
416 (70.4%)
320 (66.4%)
65 + years
19 (3.2%)
14 (2.9%)
Previous Mammography
Yes
258 (43.7%)
220 (45.8%)
0.79
No
254 (43.1%)
199 (41.5%)
Unknown
78 (13.2%)
61 (12.7%)
BI-RADS
BI-RADS 5 (highly
133 (22.5%)
107 (22.2%)
0.91
suggestive malignancy)
BI-RADS 4 (suspicious
458 (77.5%)
375 (77.8%)
abnormality)
Insurance
Yes
56 (9.5%)
43 (9.0%)
0.52
No
535 (90.5%)
438 (90.9%)
Income
<$10,000
428 (72.4%)
284 (58.9%)
<0.01
$10,000-$19,999
145 (24.5%)
166 (34.4%)
>$20,000
18 (3.1%)
32 (6.6%)
Travel Distance
Provider
371 (10.0±10.5)
313 (13.6±16.5)
<0.01
Diagnosing
292 (15.1±15.2)
208 (16.2±17.3)
0.43
mammography facility
Nearest mammography
591 (7.9±6.9)
482 (7.9±5.9)
0.95
facility
Status of Mammography at
Final Diagnosis
Work-up complete
562 (95.1%)
462 (95.9%)
0.55
Work-up not complete
29 (4.9%)
20 (4.2%)
* Values may not add up to 1073 due to missing
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Table 4.2. Median days to Diagnostic Resolution among Women in BCN with
Abnormal Mammogram*, by Travel Distance
Distance
n Median Days to Resolution P-value***
(Range)**
Distance to Provider
< 5 miles
212
22 (18-26)
0.99
5 - < 10 miles
151
21 (19-27)
10 - < 15 miles
108
22 (20-28)
15 + miles
173
23 (19-27)
Total
644
22 (21-24)
Distance to Diagnosing
Mammography
< 5 miles
120
22 (19-25)
0.05
5 - < 10 miles
103
21 (18-29)
10 - < 15 miles
66
26 (20-33)
15 + miles
182
29 (24-35)
Total
471
23 (21-27)
Distance to Closest
Mammography
< 5 miles
464
26 (23-28)
0.87
5 - < 10 miles
250
23 (21-28)
10 - < 15 miles
139
24 (19-29)
15 + miles
161
27 (21-29)
Total
1,014
25 (23-27)
*Bi-RADS results of 4 (suspicious abnormality) or 5 (highly suggestive of
malignancy)
** Median days are from Kaplan-Meier estimates
*** Wilcoxon Test of Equality over Strata
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Table 4.3. Median days to Diagnostic Resolution among Women in BCN with Abnormal Mammogram*, by Travel
Distance and Race
Black
White
Distance
n Median Days to p-value***
n
Median Days
p-value***
p-value****
Resolution
to Resolution
(Range)**
(Range)**
Distance to Provider
< 5 miles
147
23 (18-31)
0.79
65
21 (14-25)
0.79
<0.01
5 - < 10 miles
79
25 (19-29)
72
20.5 (14-23)
10 - < 15 miles
55
22 (19-29)
53
23 (18-31)
15 + miles
75
28 (21-37)
98
20.5 (16-24)
Total
356
24 (21-28)
288
21 (18-23)
Distance to Diagnosing
Mammography
< 5 miles
89
22 (19-29)
0.09
31
21 (11-29)
0.36
<0.01
5 - < 10 miles
50
27 (15-31)
53
21 (18-29)
10 - < 15 miles
37
32 (21-40)
29
20 (13-26)
15 + miles
108
30 (25-40)
74
27 (20-35)
Total
284
28 (24-31)
187
22 (20-26)
Distance to Closest
Mammography
< 5 miles
287
25 (22-31)
0.79
177
26 (21-28)
0.56
<0.01
5 - < 10 miles
110
29 (21-37)
140
21 (18-23)
10 - < 15 miles
73
26 (20-33)
66
19 (14-33)
15 + miles
98
28 (22-35)
63
20 (14-27)
Total
568
27 (24-29)
446
22 (21-25)
*Bi-RADS results of 4 (suspicious abnormality) or 5 (highly suggestive of malignancy)
** Median days are from Kaplan-Meier estimates
*** Wilcoxon Test of Equality over Strata
**** Kaplan-Meier curves comparison of the number of days to resolution among black and white (Log-rank test)

Table 4.4. Crude and Adjusted Hazard Ratio of Completion of Abnormal
Mammography Work-up
Distance
Incomplete Complete
Crude Hazard
Adjusted
Work-up Work-up
Ratio (CI)
Hazard Ratio
(n)
(n)
(CI)*
Distance to
Provider
< 5 miles
14
209
0.94 (0.76-1.15) 1.04 (0.84-1.29)
5 - < 10 miles
4
161
1.04 (0.83-1.30) 1.05 (0.84-1.31)
10 - < 15 miles
5
109
1.06 (0.83-1.36) 1.08 (0.84-1.38)
15 + miles
5
177
1.00
1.00
Distance to
Diagnosing
Mammography
< 5 miles
8
119
1.32 (1.04-1.67) 1.41 (1.00-1.80)
5 - < 10 miles
6
106
1.33 (1.04-1.70) 1.33 (1.03-1.72)
10 - < 15 miles
3
66
1.06 (0.80-1.42) 1.09 (0.81-1.45)
15 + miles
6
186
1.00
1.00
Distance to
Closest
Mammography
< 5 miles
24
466
1.03 (0.86-1.23) 1.03 (0.86-1.23)
5 - < 10 miles
10
253
1.12 (0.92-1.37) 1.06 (0.87-1.30)
10 - < 15 miles
10
137
0.97-0.77-1.22) 0.87 (0.69-1.10)
15 + miles
4
168
1.00
1.00
*Adjusted for race, age, previous mammogram, income, insurance, and screening
provider
CI=95% confidence limit
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Table 4.5. Adjusted Hazard Ratio of Completion of Abnormal Mammography Work-up, by Race
Black
White
Travel Distance
Incomplete Complete Crude HR (CI)
Adjusted HR Incomplet Complete Crude HR (CI)
Adjusted HR
Work-up Work-up
(CI)
e Work- Work-up
(CI)
(n)
(n)
up (n)
(n)
Distance to
Provider
< 5 miles
12
140 0.94 (0.70-1.25) 1.03 (0.77-1.39)
2
69 1.18 (0.56-1.63) 1.19 (0.85-1.66)
5 - < 10 miles
2
80 1.08 (0.79-1.50) 1.13 (0.82-1.57)
2
81 1.04 (0.77-1.42) 0.94 (0.69-1.29)
10 - < 15 miles
2
56 1.27 (0.89-1.81) 1.29 (0.90-1.85)
3
53 0.91 (0.65-1.29) 0.89 (0.63-1.26)
15 + miles
3
76
1.00
1.00
2
101
1.00
1.00
Distance to
Diagnosing
Mammography
< 5 miles
7
86 1.40 (1.04-1.87) 1.39 (1.03-1.88)
1
33 1.34 (0.87-2.05) 1.58 (1.01-2.48)
5 - < 10 miles
3
48 1.42 (1.00-2.01) 1.39 (0.97-1.99)
3
58 1.16 (0.82-1.66) 1.32 (0.91-1.92)
10 - < 15 miles
2
37 1.01 (0.69-1.48) 0.97 (0.65-1.44)
1
29 1.13 (0.73-1.76) 1.28 (0.81-2.02)
15 + miles
4
105
1.00
1.00
2
81
1.00
1.00
Distance to
Closest
Mammography
< 5 miles
17
281 1.06 (0.84-1.34) 1.06 (0.84-1.34)
7
185 0.95 (0.71-1.27) 0.97 (0.72-1.31)
5 - < 10 miles
5
109 1.05 (0.80-1.39) 0.99 (0.75-1.32)
5
144 1.09 (0.81-1.48) 1.09 (0.80-1.48)
10 - < 15 miles
5
70 0.99 (0.73-1.36) 0.91 (0.66-1.25)
5
67 0.90 (0.63-1.29) 0.83 (0.57-1.20)
15 + miles
2
102
1.00
1.00
3
66
1.00
1.00
*Adjusted for race, age, previous mammogram, income, insurance, and screening provider
HR=Hazard ratio; CI=95% confidence interval
P-value interaction: Distance to provider*race = 0.20; p-value interaction: Distance to diagnosing mammography*race = 0.79; p-value interaction to
diagnosing mammography*race = 0.80

Figure 4.1: Days to Diagnostic Resolution, by Travel Distance to the Screening
Provider
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Figure 4.2: Days to Diagnostic Resolution, by Travel Distance to the Diagnosing
Mammography Facility
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Figure 4.3: Days to Diagnostic Resolution, by Travel Distance to the Closest
Mammography Facility
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African American

European American

Log rank= 0.2871
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Figure 4.4: Days to Diagnostic Resolution, by Travel Distance to the Screening Provider and Race

Log rank= 0.5738

African American

Log rank= 0.0573

European American

Log rank= 0.5776
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Figure 4.5: Days to Diagnostic Resolution, by Travel Distance to the Diagnosing Mammography Facility and Race

African American

European American

Log rank= 0.9387
Log rank= 0.5483
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Figure 4.6: Days to Diagnostic Resolution, by Travel Distance to the Closest Mammography Facility and Race
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CHAPTER 5
TRAVEL DISTANCE TO SCREENING FACILITIES AND BREAST CANCER STAGE AT
DIAGNOSIS AMONG DISADVANTAGED WOMEN

2

2

Khang, L., S.A. Adams, S.E. Steck, J. Zhang, S. Xirasagar, D. Lydiard. To be submitted
to Cancer Epidemiology Biomarkers and Prevention or Breast Cancer Research.
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Abstract
Introduction: South Carolina has some of the largest health disparities in the nation.
Breast cancer is the most common cancer diagnosed and is the second largest cause of
cancer deaths among women in the state. Breast cancer stage at diagnosis is an important
predictor of survival and mortality. In the past decades, researchers have explored
geographic proximity to health care or mammography locations and breast cancer stage at
diagnosis. However, findings have been inconsistent between the studies. The purpose of
this study was to examine 1) whether travel distance to the screening provider and
mammography facility are associated with stage of breast cancer at diagnosis among
disadvantaged women who have screening available at no cost, 2) whether there are
racial disparities in breast cancer stage at diagnosis among women in South Carolina’s
Best Chance Network (BCN), and 3) whether there are any differences in the distribution
of breast cancer stage at diagnosis among BCN participants and non-BCN participants.
Methods: Women participating in South Carolina’s BCN between 1996 and 2009 with a
first primary breast cancer and linked to the South Carolina Central Cancer Registry were
included in the study. Racial differences in demographic characteristics and breast cancer
stage at diagnosis were tested using chi-square and t-tests. Multivariable logistic
regression was used to assess the association between travel distance and breast cancer
stage at diagnosis. Results: Among 681 women with breast cancer, there was no
statistically significant difference in the distribution of cancer stages by race (p=0.45).
There was no strong evidence that longer travel distance to the screening provider and
mammography facility was associated with late stage breast cancer at diagnosis among
women in BCN. Women in BCN had fewer in situ and localized breast cancers compared
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to non-BCN women Conclusion: There is no association between travel distance to the
screening provider and mammography facility among economically homogenous women
who have screening available at no cost.
Introduction
Among women in the United States, breast cancer is the most commonly
diagnosed cancer and is the second leading cause of cancer-related mortality (1). Using
mammography for breast cancer screening is the single most effective method of early
detection for breast cancer. Mammography can identify the cancer at an early stage, when
survival rates are at their highest. Beginning at age 40, the American Cancer Society
(ACS) recommends screening mammography on an annual basis for average-risk women
(1). However, about 38-54% of women do not maintain annual adherence to screening
mammograms (2, 3).
Breast cancer stage at diagnosis is an important determinant of survival and
mortality (4). Women with breast cancer diagnosed at advanced stage have limited
treatment options and poorer survival compared to women with early stage breast cancer.
The 5-year relative survival rates among women whose breast cancer is diagnosed while
in the regional stage are nearly four times greater than those of women whose cancer has
spread to distant (distant stage) lymph nodes or organs at the time of diagnosis (84% vs.
23%) (4). Studies consistently show that women with low-income, women having no
insurance or being under-insured, and racial/ethnic minorities are more likely to be
diagnosed with late-stage breast cancer (5-11).
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Spatial methods have been widely used in breast cancer research to understand
some of the disparities in breast cancer morbidity and mortality (12-20). A common
spatial method that has been examined is spatial accessibility to healthcare facilities.
Accessibility, such as long travel distance, can discourage women to seek routine
preventive care or screening. In the past decades, researchers have explored geographic
proximity to health care or mammography locations and breast cancer stage at diagnosis
(12-20). However, findings have been inconsistent between the studies. The inconsistent
results in the literature highlight the need for further research.
South Carolina has some of the largest health disparities in the nation (1). Breast
cancer is the most common cancer diagnosed and is the second largest cause of cancer
deaths among women in South Carolina (21). Statewide, the age-adjusted incidence of
breast cancer from 2004-2008 have remained stable at around 119 per 100,000 women
(1), with a higher age-adjusted incidence among European American (EA) women
compared to African American (AA) women (127.6 and 111.3 per 100,000 women,
respectively) (22), yet higher mortality among AA women compared to EA women (21).
To reduce the disproportionate burden of breast cancer death among
disadvantaged women in South Carolina, the Best Chance Network (BCN), which is the
state program of the National Breast and Cervical Cancer Early Detection Program
(NBCCEDP) was established in 1991. South Carolina has one of the highest proportions
of uninsured women in the nation, of which majority of these women are eligible to
enroll in the program. The majority (60%) of women in BCN are AA and reside in rural
counties (23). The BCN offers a unique opportunity to explore the relationship between
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travel distance to health facilities and breast cancer stage at diagnosis among
disadvantaged women who have screening available at no cost. Consequently, the
purpose of this study was to 1) investigate whether travel distance to the screening
provider and mammography facility are associated with breast cancer stage at diagnosis
among women participating in South Carolina’s BCN, 2) examine whether there are
racial disparities in the distribution of breast cancer stage at diagnosis among BCN
participants, and 3) examine whether there are any differences in the distribution of
breast cancer stage at diagnosis among BCN participants and non-BCN participants?
Methods
Study Setting/Participants
Study participants were women enrolled in the BCN of South Carolina, who
developed breast cancer between 1996 and 2009. These women were linked to the South
Carolina Central Cancer Registry (SCCCR) using probabilistic matching techniques with
Link Plus software. The cut-off value used for our probabilistic matching was 1. Data
from the BCN and SCCCR were linked by first name, last name, middle name (if
provided), date of birth, address, and social security number (SSN).
The SCCCR is a population-based data system that collects cancer statistics in the
state of South Carolina. From the last audit, the registry has a completeness rate of 96.9%
and an accuracy rate of 96.4%, both of which exceeded the national standard of 95%.
SCCCR also maintains a “Gold Certification” from the North American Association of
Central Cancer Registries (NAACCR) (24). Thus, the data are of high quality, validity,
and completeness.
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There were 707 women with first primary breast cancer from BCN that were
matched to the SCCCR. Only women with race/ethnicity categorized as AA and EA were
included in the sample because other individual racial or ethnic groups (n=17) did not
have sufficient numbers to make meaningful contributions to the analysis. We also
excluded 9 women with unknown breast cancer stage at diagnosis. A total of 681 women
were included in the study. To compare breast cancer stage at diagnosis between BCN
and non-BCN women, we identified 46,126 non-BCN women with breast cancer from
SCCCR between 1996 and 2009.
The study was approved by the South Carolina’s Department of Health and
Environmental Control (SC-DHEC), South Carolina Central Cancer Registry, and was
exempted from approval from the Institutional Review Board of the University of South
Carolina Office of Research.
Measures
The outcome of interest was breast cancer stage at diagnosis. Using the
Surveillance Epidemiology and End Results (SEER) Summary Staging guide (25), breast
cancer stages were dichotomized into ‘early stage’ and ‘late stage’; In situ and localized
(confined to primary site) stages were considered ‘early stage’ and regional (spread to
regional lymph nodes) or distant (cancer has metastasized) stages were categorized as
‘late stage’. Demographic characteristics obtained from BCN and SCCR for analyses
included age, race, income at time of enrollment, insurance status at time visit with the
BCN, and marital status. Race was categorized as EA and AA. Income at time of
enrollment was categorized into three groups: <$10000, $10000-$19999, and >$20000.
99

Health insurance status was categorized as Yes and No. Marital status was categorized
into five groups: single, married, separated/divorced, widowed, and unknown.
Three measures of geographic accessibility to health centers were calculated
(travel distance to the screening provider, travel distance to the diagnosing
mammography facility, and travel distance to the nearest mammography facility). The
travel distances were calculated in miles and along the road network based on point
location of residence (at the time of diagnosis) to the facilities using ArcGIS 9.3
(Redland, CA) Network Analyst. The Method and Tiers method (26), developed by the
SC-DHEC, was used to geocode residential addresses and health facilities. All addresses,
including patients, screening providers, and diagnosing mammography facilities were
obtained from BCN. We excluded all addresses that were missing, were PO Boxes and
those that were matched to the 5-digit zip code only. Of the 681 subjects women that
matched to the SCCCR, we were able to geocode all of their addresses. There were 218
screening providers identified from BCN; however, we were able to geocode only 137
facilities due to missing addresses and PO Boxes. Due to change in data collection over
the years, a portion of the records only captured the provider where the initial referral or
screening mammography was performed. Thus, we were able to identify 314 patients
with a diagnosing mammography facility designated.
Mammography facilities identified from a regularly updated list of Food and Drug
Administration (FDA) accredited facilities (27) were geocoded and used as the closest
mammography facilities.
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Statistical Analysis
Descriptive statistics were performed for all characteristic variables. Chi-square
test and t-test were used to test for differences between demographic and race variables.
Chi-square was also used to compare breast cancer stage at diagnosis between BCN and
non-BCN women. Multivariable logistic regression was used to assess the association
between travel distance (to the screening provider, diagnosing mammography facility,
and closest mammography facility) and stage of breast cancer at diagnosis. To assess
whether travel distance was influenced by race, we created an interaction term between
travel distance and race in each of the model (travel distance to screening provider-race,
travel distance to diagnosing mammography facility-race, and travel distance to closest
mammography facility-race). All distances to the health facilities were broken into < 5
miles, 5-<10 miles, 10-<15 miles, and 15+ miles for statistical analysis. All analyses were
performed using SAS version 9.3 (Cary, NC). A two-sided alpha level of 0.05 was used
to determine significance for all tests.
Results
There were a total of 681 women with first primary breast cancer diagnosed in the
study. The majority (~54%) of the women were AA. The mean age for AA and EA
women was 55.6 (SD=6.4) and 55.3 (SD=6.6), respectively. The distribution of cancer
stage at diagnosis among all women was in situ (16.3%), localized (44.6%), regional
(35.1%), and distant (4.0%). There was no statistically significant difference in the
distribution of cancer stage at diagnosis by race (p=0.45). Interestingly, EA women had
significantly longer travel distance to the screening provider and diagnosing
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mammography facility (p<0.01 and p=0.05, respectively) compared to AA women.
However, there was no difference in travel distance to the closest mammography facility
between AA and EA. The study population characteristics are displayed in Table 5.1.
Table 5.2 displays the breast cancer stage at diagnosis among BCN women and
non-BCN women in the state of South Carolina. Women in BCN had fewer in situ and
localized breast cancer stages at diagnosis compared to non-BCN women. There was no
statistically significant difference by race in the distribution of cancer stage at diagnosis
among BCN women. However, there was a statistically significant difference between
breast cancer stage at diagnosis and race among non-BCN women, with AA women
having higher percentage of regional and distant breast cancer at diagnosis compared to
EA women.
Table 5.3 presents the crude and adjusted odds ratios predicting late stage breast
cancer at diagnosis. In both crude and adjusted analyses, we found no significant relation
between travel distance to the screening provider, closest mammography facility and
breast cancer stage at diagnosis. However, in the adjusted model, women living 5-<10
miles from their diagnosing mammography facility were 2.25 times more likely to be
diagnosed with late stage breast cancer compared to women living < 5miles from their
diagnosing facility. When stratified by race, there were no associations between travel
distance to the screening provider, diagnosing mammography facility, closest
mammography facility, and breast cancer stage at diagnosis (Table 5.4).
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Discussion
The main purpose of this investigation was to examine whether travel distance
to the screening provider and mammography facility were associated with stage of
breast cancer at diagnosis. To our knowledge this is the first study to use geospatial
methods to examine this relationship among disadvantaged women who have screening
available at no cost. In this analysis of women participating in South Carolina’s BCN, we
found no convincing evidence that longer travel distance to the screening provider,
diagnosing mammography facility, and closest mammography facility were associated
with late stage breast cancer at diagnosis.
Our findings, though not what might be expected, are in agreement with some
other studies that found no association between travel time and breast cancer stage at
diagnosis (12-17). The lack of an association in the present study may reflect the BCN
context. BCN is a network of public and private partnerships with more than 250 health
care providers offering screening and follow-up services to disadvantaged women in the
state. South Carolina is a relatively rural state and one might expect longer travel distance
to health facilities among its residents. However, with an extensive BCN network
providing service throughout the state, we found the mean travel distance to the screening
provider is 10.9 miles (SD=10.5), diagnosing mammography facility is 14.6 miles
(SD=15.8), and closest mammography facility is 8.1 miles (SD=6.5). One study found
that among individuals living in rural Upper Great Plains states of Montana, North
Dakota, South Dakota, and Wyoming had an average travel distance of 17 miles to health
care services (28). With much shorter travel distance to screening providers and
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mammography facilities, travel distance may not be a major issue in our population. It
could also be that the program, with its financial access, is providing adequate service for
those with geographic distance challenges.
One important aspect of our study was that we were able to compare breast cancer
stage at diagnosis among BCN women to non-BCN women in the State of South
Carolina. Though BCN women had slightly greater number of late stage breast cancers
compared to non-BCN women, we found no evidence of racial disparity in breast cancer
stage at diagnosis among women in BCN. This is evidence that the program is meeting
established program standards of reducing health disparities among racial/ethnic groups.
The results of this study should be interpreted with consideration of several
limitations. First, BCN and SCCCR collect minimal data elements; therefore, we did not
have information on important factors that may contribute to stage of diagnosis, such as
family history, body mass index, and other comorbidities. Though we used road network
to measure the distance from patient’s residence to the screening provider and
mammography facility, we had no information on the mode of transportation. The type of
transportation a patient uses can affect whether a patient will seek health care or not. It
has been shown that transportation is an important factor in screening for breast cancer
(29). A study in rural North Carolina found that individuals who had a driver’s license
had twice as many health care visits compared to those who did not (30). Though women
in our study were successfully geocoded to the exact street address, the geocoded address
may not be the actual location of residence. This can happen due to new developments,
rural areas or streets that are not captured by the geocoding data. We expect this will be
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improved as geocoding expands. Another limitation is that we excluded many of the
women with non-geocodeable address. These women may reside in more rural areas and
may have long travel distance to the health facilities or vice versa. How much this bias
our finding is unknown.
There are many strengths to this investigation. The major strength is that we
were able to calculate travel distance from the exact street address of the women’s
residence to the screening facilities. This method allowed us to depict a more accurate
measurement of travel distance. Though we found no relationship between travel
distance to the health facilities and breast cancer stage at diagnosis, we were able to
calculate travel distance to the diagnosing mammography facility. Women may not
utilize the nearest facility due to personal and neighborhood characteristics, such as hours
of operation, conveniently located, and location to work. Relying on the closest
mammography facility may underestimate the true travel distance between patients’
residence and actual mammography usage if the closest facility is not the one being
utilized. Another strength of our investigation is that when we investigate the
association between travel distance to the health facilities and breast cancer stages at
diagnosis, we were able to focused on a homogenous socioeconomic status women who
have screening available at no cost. This allowed us in the design phase to eliminate some
factors (e.g. income, health insurance status, and having a provider) which may impact
breast cancer stage at diagnosis.
Previous research in this area has produced mixed results. The reasons for these
contradictory findings are unclear, but study locations (metropolitan vs. non-
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metropolitan) and geography may play a role. Research methodology can also explain the
contrary findings. There were differences in the methodology used in examining breast
cancer stage and travel distance to mammography facility among previous studies (1220). Tarvo et al. used the mean distance to the closest five mammography facilities and
found no association between travel distance and breast cancer stage at diagnosis (12).
The study in Washington by Onega et al. measured travel time instead of travel distance
and also found no relationship (16). Two studies used patient’s zip code centroid to
calculated distance to the nearest mammography facility and found that women who lived
further from the mammography facility were more likely to be diagnosed with late stage
breast cancer (19, 20).
In summary, we found no convincing evidence that longer travel distance to the
screening provider and mammography facility was associated with late stage breast
cancer at diagnosis among women participating in South Carolina’s BCN. Though
women in BCN have significantly higher proportion of late stage of breast cancer at
diagnosis compared to non-BCN women, there was no racial disparity in the distribution
of breast cancer stage at diagnosis among BCN women. Accurately capturing
accessibility to health centers, including geography and transportation method, should be
prioritized in future research.
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Table 5.1. Demographic Characteristics of the Study Population, by Race*
African American
European
(n=365) American (n=316)
Characteristics
n (%)
n (%)
p-value
n (mean±SD)
n (mean±SD)
337 (55.6±6.4)
295 (55.3±6.6)
0.58
Age
Breast Cancer Stage at
Diagnosis
In situ
67 (18.4%)
44 (13.9%)
0.45
Localized
160 (43.8%)
144 (45.6%)
Regional
125 (34.3%)
114 (36.1%)
Distant
13 (3.6%)
14 (4.4%)
Marital Status
Single
91 (25.9%)
39 (13.0%)
<0.01
Married
97 (27.6%)
116 (38.5%)
Separated/Divorced
70 (19.9%)
72 (23.9%)
Widowed
52 (14.8%)
41 (13.6%)
Unknown
41 (11.7%)
33 (11.0%)
Previous
Mammography
Yes
149 (40.9%)
145 (46.0%)
0.34
No
148 (40.7%)
122 (38.7%)
Unknown
67 (18.4%)
48 (15.2%)
Insurance
Yes
87 (23.85%)
76 (24.1%)
0.93
No
278 (76.2%)
239 (75.9%)
Income
<$10,000
250 (68.5%)
189 (59.8%)
0.03
$10,000-$19,999
101 (27.7%)
104 (32.9%)
>$20,000
14 (3.8%)
23 (7.3%)
Travel Distance
Provider
245 (9.3±9.6)
230 (12.6±12.0)
<0.01
Diagnosing
176 (13.0±14.1)
138 (16.6±17.5)
0.05
mammography
facility
Nearest
365 (8.2±7.1)
316 (8.0±5.8)
0.64
mammography
facility
* Values may not add up to 681 due to missing
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Table 5.2. Breast Cancer Stage Among BCN Women Compared to Women in the State of South Carolina, 1996-2009
BCN Women
Non-BCN Women
Breast
Total
AA
EA
pa
Total
AA
EA
pb
Cancer
Stage
In situ
111 (16.3%)
67 (18.4%)
44 (13.9%) 0.45
8,131 (17.6%) 1,846 (17.6%)
6,187 (17.6%) <0.01
Localized 304 (44.6%) 160 (43.8%) 144 (45.6%)
23,954 (51.9%) 4,660 (44.4%) 19,041 (54.2%)
Regional
239 (35.1%) 125 (34.3%) 114 (36.1%)
12,172 (26.4%) 3,354 (31.9%)
8,695 (24.8%)
Distant
27 (4.0%)
13 (3.6%)
14 (4.4%)
1,869 (4.1%)
650 (6.2%)
1,202 (3.4%)
a
P-value-comparison between AA and EA among BCN women
b
P-value-comparison between AA and EA among non-BCN women
c
P-value-comparison between BCN total women to non-BCN total women
d
P-value-comparison between BCN AA women to non-BCN AA women
e
P-value-comparison between BCN EA women to non-BCN EA women

pc

pd

pe

<0.01

0.19

<0.01
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Table 5.3. Crude and Adjusted Odds Ratios Predicting Late Stage Breast Cancer
at Diagnosis among Women in BCN, 1996-2009
Distance
Early Late Stage
Crude Odds Adjusted Odds
Stage
Breast
Ratio (CI)
Ratio (CI)*
Breast Cancer (n)
Cancer (n)
Distance to
Provider
< 5 miles
102
62
Referent
Referent
5 - < 10 miles
71
41 0.95 (0.58-1.56) 1.04 (0.60-1.79)
10 - < 15 miles
48
31 1.06 (0.61-1.84) 1.14 (0.61-2.13)
15 + miles
71
49 1.14 (0.70-1.84) 1.27 (0.74-2.18)
Distance to
Diagnosing
Mammography
< 5 miles
59
30
Referent
Referent
5 - < 10 miles
35
24 1.35 (0.68-2.66) 1.30 (0.62-2.73)
10 - < 15 miles
28
27 1.90 (0.95-3.77) 2.25 (1.04-4.83)
15 + miles
73
38 1.02 (0.57-1.85) 1.13 (0.59-2.14)
Distance to
Closest
Mammography
< 5 miles
187
112
Referent
Referent
5 - < 10 miles
105
60 0.95 (0.64-1.42) 0.91 (0.59-1.40)
10 - < 15 miles
63
44 1.17 (0.74-1.83) 1.13 (0.68-1.88)
15 + miles
60
50 1.39 (0.89-2.17) 1.50 (0.94-2.41)
* Adjusted for age at diagnosis, race, income, insurance status, and marital status
CI=Confidence interval

109

110

Table 5.4. Crude and Adjusted Odds Ratios Predicting Late Stage Breast Cancer at Diagnosis among Women in BCN, by Race
Black
White
Travel Distance
Early
Late
Crude OR(CI)
Adjusted OR
Early
Late Crude OR (CI)
Adjusted OR
Stage
Stage
(CI)*
Stage
State
(CI)*
Cancer Cancer
Cancer Cancer
(n)
(n)
(n)
(n)
Distance to
Provider
< 5 miles
66
42
Referent
Referent
36
20
Referent
Referent
5 - < 10 miles
31
23 1.17 (0.60-2.26) 1.28 (0.61-2.70)
40
18 0.81 (0.37-1.77)
0.70 (0.30-1.64)
10 - < 15 miles
24
11 0.72 (0.32-1.62) 0.55 (0.20-1.49)
24
20 1.50 (0.67-3.36)
1.69 (0.69-4.11)
15 + miles
31
17 0.86 (0.43-1.75) 1.23 (0.57-2.66)
40
32 1.44 (0.70-2.95)
1.24 (0.55-2.79)
Distance to
Diagnosing
Mammography
< 5 miles
42
20
Referent
Referent
17
10
Referent
Referent
5 - < 10 miles
16
12 1.58 (0.63-3.95) 1.34 (0.48-3.79)
19
12 1.07 (0.37-3.11)
0.72 (0.21-2.45)
10 - < 15 miles
17
15 1.85 (0.77-4.45) 2.09 (0.75-5.84)
11
12 1.85 (0.59-5.75)
1.52 (0.42-5.49)
15 + miles
32
22 1.44 (0.68-3.09) 1.35 (0.58-3.17)
41
16 0.66 (0.25-1.75)
0.61 (0.21-1.78)
Distance to
Closest
Mammography
< 5 miles
108
65
Referent
Referent
79
47
Referent
Referent
5 - < 10 miles
53
18 0.56 (0.31-1.05) 0.60 (0.31-1.18)
52
42 1.36 (0.79-2.34)
1.16 (0.64-2.11)
10 - < 15 miles
33
23 1.16 (0.63-2.14) 1.07 (0.53-2.16)
30
21 1.18 (0.61-2.29)
1.08 (0.51-2.26)
15 + miles
33
32 1.61 (0.91-2.87) 1.72 (0.92-3.21)
27
18 1.12 (0.56-2.25)
1.02 (0.60-2.63)
* Adjusted for age at diagnosis, race, income, insurance status, and marital status
OR= Odds ratio; CI=Confidence interval
P-value interaction: Distance to provider*race = 0.23; p-value interaction: Distance to diagnosing mammography*race = 0.56; p-value
interaction: Distance to closest mammography*race = 0.09
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CHAPTER 6
TRAVEL DISTANCE TO SCREENING REFERRAL PROVIDER, MAMMOGRAPHY
FACILITY, AND BREAST CANCER MORTALITY AMONG WOMEN IN A STATE
BREAST CANCER SCREENING PROGRAM

3

3

Khang, L., S.A. Adams, S.E. Steck, J. Zhang, S. Xirasagar, D. Lydiard. To be submitted
to Cancer Epidemiology Biomarkers and Prevention or Breast Cancer Research.
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Abstract
Introduction: The death rates from breast cancer have declined in the past decades;
however, disparities between racial/ethnic groups remain. South Carolina has some of the
largest health disparities in the nation, particularly breast cancer morbidity and mortality.
The Best Chance Network was established to reduce the burden of breast cancer among
disadvantaged women in the state. Although much has been done to identify factors
related to breast cancer mortality, little has been done to examine the influence of
geographic accessibility to health facilities and breast cancer mortality. The purpose of
this study was to investigate whether travel distance to the screening referral provider and
mammography facility are associated with breast cancer-specific and all-cause mortality
among women participating in South Carolina’s Best Chance Network. We also sought to
contrast and compare by race breast cancer-specific and all-cause survival among BCN
participants. Methods: Women in South Carolina’s Best Chance Network, who
developed breast cancer between 1996 and 2009 and self-identified as either African
American (AA) or European American(EA) (n=690), were included in the study. Chisquare and t-tests were used to determine racial differences in characteristics among the
women. Kaplan-Meier survival methods were used to determine the breast cancerspecific and all-cause survival probabilities. Cox proportional hazard modeling was used
to assess the relationship between travel distance and mortality (breast cancer-specific
and all-cause mortality). Results: There were no statistically significant differences in
breast cancer-specific and all-cause survival proportions between AAs compared to EAs.
Women with 10+ miles of travel distance to the diagnosing mammography facility had ~
2 fold excess risk of death from breast cancer (HR, 2.32; 95% CI, 1.12-4.80). However,
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the association was no longer statistically significant after adjustment for various
prognostics characteristics. In the adjusted model, there was no association between
travel distance to the health centers and mortality (breast cancer-specific and all-cause
mortality) among EA and AA women. Conclusion: We found no racial disparity in
breast cancer-specific and all-cause survival among economically disadvantaged women
participating in BCN. There is little evidence that geographic accessibility to these health
facilities influence breast cancer-specific and all-cause mortality among women in a
homogenous socioeconomic status.
Introduction
In 2012, the American Cancer Society estimates approximately 226,870 new
cases and 39,920 deaths from breast cancer among women in the United States (1).
Although the overall death rates for breast cancer have declined in the past decades, the
mortality rates differ among racial/ethnic and age groups (1, 2). Even though European
American (EA) women have higher breast cancer rates, African American (AA) women
are more likely to die from the cancer (2).
Breast cancer is the second largest cause of cancer deaths among women in South
Carolina (3). The age-adjusted mortality rate in South Carolina from 2004-2008 have
remained stable at ~ 24.3 per 100,000 women (1), with AA women having higher ageadjusted mortality rate compared to EA women (31.2 and 22.2 per 100,000 women,
respectively) (2). To reduce breast cancer disparities in South Carolina, the Best Chance
Network (BCN), which is the state program of the National Breast and Cervical Early
Detection Program (NBCCEDP), was established in 1991. The program provides free
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mammograms, clinical breast exams, Pap tests, pelvic exams, diagnostic procedures, case
management, community education on breast/cervical cancer and early detection for
underserved women aged 47-64 years, who are at or below 200% of the Federal trade
poverty level, and those who lack insurance or have insurance that only covers hospital
care.
Studies have shown that breast cancer stage at diagnosis (4), age (5), race (2, 4),
socioeconomic status (6), lifestyle (7-9), tumor characteristics (10-11), and reproductive
factors (12-14) are associated with breast cancer mortality and survival. There have been
several studies that examined travel distance to the mammography facility and breast
cancer stage at diagnosis (15-23); however, little has been done to examine geographic
accessibility to the screening referral provider, mammography facility, and its association
with breast cancer mortality. Consequently, the objective of this study was to 1)
investigate whether travel distance to the screening referral provider and mammography
facility are associated with breast cancer-specific and all-cause mortality among women
participating in South Carolina’s BCN, and 2) to contrast and compare by race breast
cancer-specific and all-cause survival among BCN participants . These women are
homogeneous in terms of their socioeconomic status and they all have access to free
screening, which will allow us to look at the independent effects of distance and cancer
mortality.
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Methods
Study Setting/Participants
The setting of this study was the Best Chance Network of South Carolina. The
program is a network consisting of public and private partnerships between health clinics
and radiology facilities to provide free mammograms, clinical breast exams, Pap tests,
pelvic exams, diagnostic procedures, case management, community education on
breast/cervical cancer and early detection for disadvantaged women (below 200% of the
Federal trade poverty level and those who lack insurance coverage) in the state. From the
BCN, women with breast cancer confirmed and linked to the South Carolina Cancer
Registry (SCCCR) between 1996 and 2009 were included in the current analyses.
Demographic information from women with breast cancer in BCN were linked to the
SCCCR using probabilistic matching techniques by first name, last name, middle name
(if provided), date of birth, address, and social security number (SSN). The cut-off score
of 1 was used in Link Plus for the probabilistic matching.
From 1996 to 2009, there were 707 women with a first primary breast cancer
diagnosed from BCN that were matched to the SCCCR. Due to the small sample of other
ethnic groups (n=17), only women with race/ethnicity African American (AA) and
European American (EA) were included in the study, leaving a total sample of 690
women for inclusion in the study. The study was approved by the South Carolina’s
Department of Health and Environmental Control (SC-DHEC), South Carolina Central
Cancer Registry, and was exempted from approval from the Institutional Review Board
of the University of South Carolina Office of Research.
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Distance variables
Three travel distance variables were calculated: travel distance to the screening
referral provider, travel distance to the diagnosing mammography facility, and travel
distance to the nearest mammography facility. ArcGIS 9.3 (Redland, CA) Network
Analyst was used to calculate the travel distance in miles along the road network based
on point location of residence to the facilities. Patients’ addresses, screening referral
providers’ addresses, and diagnosing mammography facilities’ addresses were obtained
from BCN. The closest mammography facilities were identified from the Food and Drug
Administration’s (FDA) list of accredited facilities (24). All addresses were geocoded
using the Method and Tiers method (25) developed by the SC-DHEC Informatics
Division.
Residential addresses among all 690 women were successfully geocoded to the
exact street address. For all of the 690 women, we were able to calculate distance to the
closest mammography facilities. Only 481 women had a screening referral provider’s
address and 319 women had a diagnosing mammography facility recorded. Hence, we
were only able to calculate travel distance to the screening referral provider and
diagnosing mammography facility for these women.
Outcomes
The outcome of interest was breast cancer-specific and all-cause mortality. To
determine breast cancer-specific mortality, we looked at the “Sequence Number” and the
“Cause of Death” from the cancer registry data. If the “Sequence Number” was “00”,
meaning that the subject had one malignant primary in her lifetime, and the “Cause of
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Death” was “Cancer”, then the death was related to breast cancer. If the subject died of
any cause of death, including breast cancer, then the death was considered all-cause
mortality.
Covariates
Patients’ characteristics were obtained from the BCN and SCCCR, which
included age, race, breast cancer stage, estrogen receptor status, marital status, health
insurance, income, and first course of treatment. Breast cancer stage at diagnosis was
categorized as in-situ, localized, regional, and distant. Estrogen receptor (ER) status was
categorized as positive, negative, and borderline. Income at time of enrollment was
categorized into three groups: <$10000, $10000-$19999, and >$20000. Health insurance
status was categorized as Yes or No. Marital status was categorized into married or not
married. Cancer treatments were categorized as surgery, radiation, chemotherapy,
hormonal therapy, and none.
Statistical Analysis
Descriptive statistics were calculated for all characteristics variables. Chi-square
tests and t-tests were used to examine the associations between characteristics variables
and race. Survival probabilities for breast cancer-specific and all-cause mortality were
examined using Kaplan-Meier survival method. Cox proportional hazard modeling was
used to assess the relationship between mortality and travel distance to the screening
referral provider, diagnosing mammography facility, and closest mammography facility.
To assess whether travel distance was influenced by race, we created an interaction term
between travel distance and race in each of the Cox proportional hazard model (travel
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distance to screening provider-race, travel distance to diagnosing mammography facilityrace, and travel distance to closest mammography facility-race). Travel distance was
broken into <5 miles, 5-<10 miles, 10-<15 miles, and 15+ miles. However, due to low
sample size in some categories, distances were grouped into <10 miles and 10+ miles for
analysis.
Individuals not found to be deceased at the end of the time period, December 31,
2009, were considered to be alive at the time of censoring. For breast cancer specific
mortality, non-cancer cause of death and cancer death other than breast cancer were also
considered censored. The proportional hazards assumption was examined through the
logarithm of negative logarithm of survival probability with logarithm of time and the
Schoenfeld residuals were further evaluated to confirm that there were no violations of
the assumption. Missing data were excluded from analyses. All analyses were done using
SAS statistical software version 9.3 (Cary, NC). All statistical tests were 2-sided with a
P-value of ≤ 0.05 used to determine statistical significance.
Results
Our study samples consisted of slightly more AA women compared to EA women
(53.6% vs 46.4%, respectively). The mean age of the women was ~ 55 years old
(standard deviation [SD] =6.7). The average travel distance to the screening provider,
diagnosing mammography facility, and closest mammography facility were 10.8 miles
(SD=10.9 miles), 14.4 miles (SD=15.7 miles), and 8.1 miles (SD=6.5 miles),
respectively. EA women had significantly longer travel distance to the screening provider
and diagnosing mammography facility compared to AA women. There were 90 breast
121

cancer specific deaths and 133 all-cause deaths. Table 6.1 presents the study population
characteristics by race.
Figure 6.1 and 6.2 display the survival proportions for breast cancer-specific and
all-cause among AA and EA women. There were no significant racial differences in the
overall 5-year survival proportions for breast cancer-specific (~87% for EA women and
~85% for AA women, P = 0.64) and all-cause mortality (~81% for EA women and ~80%
for AA women, P = 0.90).
Table 6.2 presents the results of the Cox proportional hazards models for breast
cancer-specific and all-cause mortality. There was no association between travel distance
to the screening referral provider, diagnosing mammography facility, closest
mammography facility and all-cause mortality. Women with 10+ miles of travel distance
to the diagnosing mammography facility had ~ 2.3-fold excess risk of death from breast
cancer compared to those with < 10 miles of travel distance (hazard ratio [HR], 2.32;
95% confidence interval [CI], 1.12-4.80). However, after adjustment for age, race, ER
status, marital status, income, insurance status, breast cancer stage at diagnosis, and
treatment, the association was no longer statistically significant. Women with 10+ miles
of travel distance to the closest mammography facility also had excess risk of death from
breast cancer compared to those with < 10 miles of travel distance to the closest
mammography facility (HR, 1.83; 95% CI, 1.21-2.77). The association was also not
significant after adjustment for covariates.
Table 6.3 presents the Cox proportional hazard analyses for breast cancer-specific
mortality by race. After adjustment for age, ER status, marital status, income, insurance
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status, breast cancer at diagnosis, and treatment, there was no association between travel
distance to the health centers and mortality (breast cancer-specific and all-cause
mortality) among both race groups. However, in the crude model for breast cancerspecific, both AA and EA women who lived 10+ miles from the closest mammography
facility had an increased risk of death from breast cancer compared to those who lived <
10 miles (HR=1.75 [95% CI=1.00-3.05 and HR=1.93 [95% CI=1.04- 3.60], respectively).
The Cox proportional hazard analyses for all-cause mortality, by race, are
displayed in table 6.4. There was no association between travel distance to the screening
referral provider, diagnosing mammography facility, closest mammography facility and
all-cause mortality among EA and AA women.
Discussion
The purpose of this study was to assess whether travel distance to the screening
referral provider, diagnosing mammography facility, and closest mammography facility
are associated with breast cancer mortality and all-cause mortality among women in the
BCN of South Carolina. The overall breast cancer-specific 5-year survival rate among
women in BCN was ~86%. We found no significant racial differences in the overall 5year survival rate for breast cancer-specific and all-cause mortality among EA and AA
women. Interestingly, the breast cancer-specific survival rate among AA women (~85%)
was much higher than the United States national average of ~77% (2).
We found no evidence that longer travel distance to the screening referral
provider, diagnosing mammography facility, and closest mammography was associated
with all-cause mortality. In our crude analysis for breast cancer-specific mortality,
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women who lived 10+ miles from their diagnosing mammography facility and closest
mammography facility had increased risk of breast cancer mortality compared to those
who lived < 10 miles from the facility. However, the association diminished once we
controlled for other characteristics. The null finding was similar to a study in Northern
England, which found no association between travel time to the general practitioners and
breast cancer survival (26). This study looked at approximately 28,000 breast cancer
cases from the Northern and Yorkshire Cancer Registry & Information Service
(NYCRIS) and found that patients living further from the general practitioner were not
associated with breast cancer survival. However, they found an inverse association with
travel time to the hospital and breast cancer survival; women living further from the
hospital had a better chance of breast cancer survival compared to those living the
closest. Though the population of this study may not be comparable to those in the BCN,
similar findings were observed.
The findings from this study are subject to several limitations. One limitation of
this study is that we had limited data on potentially important covariates. BCN and
SCCCR collect minimal data for reporting purpose and we have no information on some
of the important factors (e.g. family history, body mass index, lifestyle, and other
comorbidities) that contribute largely to breast cancer mortality and survival. We also
have limited data on tumor characteristics, such as Her-2/neu expression and
progesterone receptor status, which also affect breast cancer mortality. Another limitation
is that we have no information on the mode of transportation that the women use to get
services from these facilities. Studies have shown that the type of transportation can
affect health care visits (27, 28). Though all addresses were successfully geocoded, the
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geocoded address may not be the actual location of residence. This can happen due to
new developments, rural areas or streets that are not stored in the geocoding map. Due to
the demographic of our sample, which are mostly low income and uninsured women, the
findings may not be generalizeable to other populations.
Our study also has several strengths. To our knowledge, this is first study to
investigate whether travel distance influence breast cancer-specific and all-cause
mortality among disadvantaged women in a funded program, which aims at improving
breast and cervical health disparities. Another strength of this study was that we were
able to compute travel distance from the exact street address of the women’s residence to
the health facilities, which is a more accurate measurement of travel distance compared to
using straight line or eulicudean distance. An additional strength was we were able to
estimate travel distance based on the actual use of the mammography facility by using
patient’s diagnosing mammography facility and residence at time of diagnosis.
We found no racial disparities in breast cancer-specific and all-cause mortality
among women in BCN. The findings in this study may be unique, because our population
was from a program that was established to provide adequate screening and follow-up
among women who enter the program; therefore, we see no racial disparities. These
findings may reveal that the program is meeting established program standards of
reducing health disparities among racial/ethnic groups.
There was no association between travel distance to the screening referral
provider, diagnosing mammography facility, closest mammography facility and all-cause
or breast cancer mortality after adjustment for several covariates. Though not what
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expected, we were not surprised with these null findings because our previous study (not
yet published) did not find any convincing evidence that travel distance to the screening
referral provider and mammography facility was associated with breast cancer stage of
diagnosis. If we had found that travel distance to these facilities was associated with
breast cancer stages at diagnosis, then we would have expected to find an association.
In conclusion, these findings suggest that geographic accessibility to these health
facilities (screening referral provider, diagnosing mammography facility, and closest
mammography facility) may not be a mediator to breast cancer mortality and survival
among women in programs like BCN. Further research should be conducted of similar
programs like BCN and in other parts of the country to confirm these findings. The
geography from where our population came from was relatively rural and may not be
generalized. Future research that examines factors which may affect geographic
accessibility, such as mode of transportation, should also be investigated.
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Table 6.1. Demographic Characteristics of the Study Population, by Race*
Black (n=370)
White (n=320)
Characteristics
n (mean±SD)
n (mean±SD)
370 (55.6±6.7)
320 (55.4±6.6)
Age
Travel Distance
Provider
248 (9.3±9.6)
233 (12.5±12.0)
Diagnosing
179 (12.6±14.1)
140 (16.4±17.5)
mammography facility
Nearest mammography
370 (2.46±1.19)
320 (2.54±1.03)
facility
n (%)
n (%)
All Cause of Deaths
Dead
70 (18.9%)
63 (19.7%)
Alive
300 (81.1%)
247 (80.3%)
Breast Cancer Deaths
Dead
50 (13.5%)
40 (12.5%)
Alive
320 (86.5%)
280 (87.5%)
Breast Cancer Stage at Diagnosis
In situ
67 (18.4%)
44 (13.9%)
Localized
160 (43.9%)
144 (45.6%)
Regional
125 (34.3%)
114 (36.1%)
Distant
13 (3.6%)
14 (4.4%)
Behavior of Cancer
In-situ
67 (18.1%)
44 (13.8%)
Invasive
303 (81.9%)
276 (86.3%)
Estrogen Receptor Status
Positive
115 (60.5%)
115 (74.2%)
Negative
75 (39.5%)
38 (24.5%)
Borderline
0 (0.0%)
2 (1.3%)
Marital Status
Unmarried
214 (68.2%)
153 (56.7%)
(single/separated/divorced)
Married
100 (31.8%)
117 (43.3%)
Insurance
Yes
87 (23.5%)
77 (24.1%)
No
283 (76.5%)
242 (75.9%)
Income
<$10,000
254 (68.7%)
190 (59.4%)
$10,000-$19,999
102 (27.6%)
107 (33.4%)
>$20,000
14 (3.8%)
23 (7.2%)
Treatment
Surgery only
91 (43.1%)
73 (42.9%)
Surgery, radiation
36 (17.1%)
35 (20.6%)
Surgery, radiation, chemotherapy
50 (23.7%)
21 (12.4%)
Surgery, radiation, chemotherapy,
18 (8.5%)
26 (15.3%)
hormone
Hormone only
0 (0.0%)
2 (1.2%)
None
16 (7.6%)
13 (7.7%)
* Missing were excluded; number may not add up to total
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p-value
0.75
<0.01
0.05
0.36

0.80

0.69

0.45

0.12

<0.01

<0.01

0.85

0.02

0.02

Figure 6.1: Breast Cancer Survival among Women in BCN, by Race
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Figure 6.2: All-Cause Mortality Survival among Women in BCN, by Race

129

130

Table 6.2. Crude and Adjusted Hazard Ratios for Breast Cancer-Specific and All-Cause Mortality among Travel Distance 10+
miles Compared with < 10 Miles
Breast Cancer Deaths
All Deaths
Variables
Deaths PersonCrude HR
Adjusted HR
Deaths Person- Crude HR (95%
Adjusted HR
(n)
Years
(95% CI)
(95% CI)*
(n)
Years
CI)
(95% CI)*
Distance to
Provider
< 10 miles
36
1116
Referent
Referent
53
1158
Referent
Referent
10 + miles
27
833 1.03 (0.63-1.70)
1.03 (0.33-3.16)
36
856
0.93 (0.61-1.42) 0.86 (0.32-2.30)
Distance to
Diagnosing
Mammography
< 10 miles
10
647
Referent
Referent
19
677
Referent
Referent
10 + miles
26
759 2.32 (1.12-4.80)
2.21 (0.68-7.21)
32
772
1.50 (0.85-2.65) 1.46 (0.58-3.65)
Distance to
Closest
Mammography
< 10 miles
47
2129
Referent
Referent
79
2228
Referent
Referent
10 + miles
43
1045 1.83 (1.21-2.77)
2.14 (0.95-4.83)
54
1101
1.38 (0.98-1.96) 1.81 (0.89-3.69)
* Adjusted for race, age, estrogen receptor, marital status, income, insurance, treatment, and breast cancer stage at diagnosis
HR=Hazard ratios; CI=Confident Intervals
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Table 6.3. Crude and Adjusted Hazard Ratios for Breast Cancer-Specific Mortality among Travel Distance 10+ miles
Compared with < 10 Miles, by Race
African American
European American
Variables
Deaths Person
Crude HR
Adjusted HR
Deaths Person
Crude HR
Adjusted HR
(n)
-Years
(95% CI)
(95% CI)*
(n)
-Years
(95% CI)
(95% CI)*
Distance to
Provider
< 10 miles
25
596
Referent
Referent
11
520
Referent
Referent
10 + miles
9
394 0.59 (0.27-1.26)
3.32 (0.4218
439 1.92 (0.91-4.08) 3.64 (0.52-25.68)
26.04)
Distance to
Diagnosing
Mammography
< 10 miles
6
365
Referent
Referent
4
281
Referent
Referent
10 + miles
14
355 2.61 (1.00-6.79)
2.71 (0.5912
404 2.17 (0.70-6.75) 2.18 (0.07-68.69)
12.47)
Distance to
Closest
Mammography
< 10 miles
26
1109
Referent
Referent
21
1020
Referent
Referent
10 + miles
24
573 1.75 (1.00-3.05) 1.53 (0.51-4.59)
19
472 1.93 (1.04-3.60) 3.44 (0.91-12.93)
* Adjusted for age, ER, marital status, income, insurance, treatment, and breast cancer stage at diagnosis
Interaction: Distance to provider*race=0.69; Interaction: Distance to diagnosing mammography facility= 0.96;Interaction: Distance to
closest mammography facility= 0.49
HR=Hazard ratios; CI=Confident Intervals
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Table 6.4. Crude and Adjusted Hazard Ratios for All-Cause Mortality among Travel Distance 10 + Miles Compared with < 10
Miles, by Race
African American
European American
Variables
Deaths Person
Crude HR
Adjusted HR
Deaths Person
Crude HR
Adjusted HR
(n)
-Years
(95% CI)
(95% CI)*
(n)
-Years
(95% CI)
(95% CI)*
Distance to
Provider
< 10 miles
34
616
Referent
Referent
19
542
Referent
Referent
10 + miles
10
399 0.49 (0.24-0.98) 1.34 (0.23-7.97)
26
456 1.65 (0.91-2.98) 2.83 (0.60-13.27)
Distance to
Diagnosing
Mammography
< 10 miles
12
391
Referent
Referent
7
286
Referent
Referent
10 + miles
16
364 1.49 (0.70-3.14) 1.69 (0.51-5.63)
16
408 1.64 (0.67-3.99)
1.98 (0.47-8.31)
Distance to
Closest
Mammography
< 10 miles
39
1160
Referent
Referent
40
1067
Referent
Referent
10 + miles
31
611 1.51 (0.94-2.42) 1.33 (0.50-3.56)
23
490 1.25 (0.75-2.09)
2.59 (0.86-7.86)
* Adjusted for age, ER, marital status, income, insurance, treatment, and breast cancer stage at diagnosis
Interaction: Distance to provider*race=0.92; Interaction: Distance to diagnosing mammography facility=0.21 ;Interaction: Distance to
closest mammography facility= 0.65
HR=Hazard ratios; CI=Confident Intervals
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CHAPTER 7
SUMMARY
Breast cancer is the most commonly diagnosed cancer and is the second cause of
cancer-related mortality among women in the United States (1). In South Carolina, breast
cancer is the most common cancer diagnosed and is the second largest cause of cancer
deaths among women in the state (2). Statewide, the age-adjusted incidence of breast
cancer from 2002-2006 have remained stable at around 119 per 100,000 women (2), with
a higher age-adjusted incidence among European American women compared to African
American women (127.6 and 111.3 per 100,000 women, respectively) (2, 3). However,
African American women had a 39% higher mortality rate compared to European
American women (4). This disparity may be due to breast cancer tumor characteristics (5,
6) and difference in access/utilization of early detection and treatments among African
American women (7, 8).
Early screening is the single most effective method in reducing mortality from the
disease (1). Annual mammography with adequate follow-up is estimated to result in
reductions in mortality ranging from 25% to 44% (9-15). Despite the benefit of
mammography, many women do not maintain annual adherence to screening
mammograms (16) and complete follow-up after having an abnormal mammogram
screening (17, 18).
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Minority, uninsured, and lower socioeconomic status women often do not have
access to early detection (19). These women are less likely to utilize mammography
screening (19-21), less likely to have timely and complete follow-up after an abnormal
mammography screening (22), more likely to be diagnosed with advanced-stage breast
cancer (23), and have poorer survival (24). To reduce the disproportionate burden of
breast cancer among women in South Carolina, the Best Chance Network (BCN) was
established to offer screening and follow-up services to disadvantaged women in the
state.
This dissertation was designed to assess travel distance to the health facilities
(screening referral provider, diagnosing mammography facility, closest mammography
facility) and its relationship with completion of abnormal mammography follow-up,
breast cancer stage at diagnosis, and mortality among women in the BCN program. A
retrospective cohort study that covers a period of 14 years between 1996 and 2009 was
used to investigate travel distances (to the screening referral provider, diagnosing
mammography facility, and closest mammography facility) and completion of abnormal
mammography follow-up, breast cancer stage at diagnosis, and mortality among women
in the BCN program.
In the following pages, the results from each aim are summarized and discussed.
Aim 1(Chapter 4): Travel distance to screening facilities and completion of
abnormal mammography follow-up among disadvantaged women
In aim 1, we examined the relationship between travel distance to the screening
referral provider, diagnosing mammography facility, closest mammography facility, and
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completion of abnormal mammogram follow-up among women in the BCN program.
Inadequate screening or incompletion of abnormal mammogram follow-up after an
abnormal mammogram screening can contribute to poor cancer survival. Factors
associated with mammography and inadequate screening have been scrutinized in
numerous studies, which includes patients characteristics, socioeconomic status,
insurance status, having a primary health care provider, recommendations for screening
from primary health care providers, lack of transportation, language barriers, concern
about the effects of radiation, and fear of cancer (25-30). From a recent review of the
literature, there has been no study examining distance to the screening referral provider,
mammography facilities, and its effect on completion of abnormal follow-up. The finding
from this aim contributes to some of the known factors relating to inadequate breast
cancer screening.
We found that women who lived further from their diagnosing mammography
facility had longer day to resolution (completion of abnormal mammographic finding)
compared to those who lived the closest (p=0.05). AA women had significantly longer
day to resolution compared to EA women; the largest difference in median day to
resolution was in travel distance to the diagnosing mammography facility (28 days for
AA women vs. 22 days for EA women). We also found that women who lived closest to
the diagnosing mammography facility were more likely to have an abnormal
mammographic follow-up completion compared to those who lived the farthest. When
stratified by race, we still see the association among AA and EA women for the adjusted
model.
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One important aspect of this aim was our sensitivity analysis using travel distance
to the diagnosing mammography facility compared with travel distance to the closest
mammography facility. We observed no association between completion of abnormal
mammogram follow-up and travel distance to the closest mammography facility, but we
found an association with travel distance to the diagnosing mammography facility.
Women were more likely to have their abnormal mammogram follow-up completed if
they were living closest to their diagnosing mammography facility. Choosing a facility
for screening may not always be the closest to home due to various factors, such as
personal preference, neighborhood characteristics, and hours of operation. Relying on the
closest mammography facility to calculate the travel distance may not portrait an accurate
distance.
Aim 2(Chapter 5): Travel distance to screening facilities and breast cancer stage at
diagnosis among disadvantaged women
The purpose of this aim was 1) to investigate whether travel distance to the
screening provider and mammography facility was associated with stage of breast cancer
at diagnosis, 2) are there racial disparities in breast cancer stage at diagnosis among
women in BCN, and 3) are there a difference in the distribution of breast cancer stage at
diagnosis among BCN participants and non-BCN participants? Breast cancer stage at
diagnosis is an important factor in survival and mortality (1). Women with breast cancer
diagnosed at advanced stage have limited treatment options and poorer survival
compared to women with early stage breast cancer. The 5-year relative survival rate
among women whose breast cancer is diagnosed while in the regional stage are nearly
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four times greater than those of women whose cancer has spread to distant (distant stage)
lymph nodes or organs at the time of diagnosis (84% vs. 23%) (1). Many studies have
examined travel time/distance to health care or mammography facility and breast cancer
stage at diagnosis (31-39); however, findings have been inconsistent between the studies.
The inconsistent results may be due to geographical locations and density of population
or mammography facilities in the area. Nevertheless, almost all of these studies used the
closest mammography facility to calculate the travel distance/time. In our study, we were
able to use all three health facilities (screening referral provider, diagnosis mammography
facility, and closest mammography facility).
In the crude models, we found no significant relationship between travel distance
and breast cancer stage at diagnosis. However, when we adjusted for age, race, income,
insurance status, and marital status, we found that women living 10-15 miles from their
diagnosing mammography facility were 2.25 times (95% CI=1.04-4.83) more likely to
be diagnosed with late stage breast cancer compared to those living less than 5 miles
from their diagnosing mammography facility. We found no association (both in the crude
and adjusted model) among EA and AA women in the BCN.
Among women in the BCN, there was no difference in the distribution of cancer
stages and race (p-value=0.45). However, there was statistically significant difference
between breast cancer stage at diagnosis and race among non-BCN women (pvalue<0.01), with AA women had higher percentage of regional and distant breast cancer
at diagnosis compared to EA women.
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Our null findings, though not what we expected, is similar to six studies that
found no association between travel distance to the mammography facility and breast
cancer stage at diagnosis (31-36). From a literature search, there were three studies that
found an association (37-39). However, all of them used the closest mammography
facility as the facility of utilization and they used zip code centroids to compute the travel
distance.
All of these studies that examined this relationship had no information on
patients’ mammography utilization. By using the nearest mammography facility, a patient
may not utilize this facility due to various reasons. Relying on the closest mammography
facility may underestimate the true travel distance between patients’ residence and actual
mammography usage if the closest facility is not the one being utilized.
Aim 3(Chapter 6): Travel distance to screening referral provider, mammography
facility, and breast cancer mortality among women in a state breast cancer
screening program
In aim 3, we investigated the association between travel distance to the screening
referral provider, mammography facility, and cancer-specific and all-cause mortality
among women in BCN. We also contrasted and compared breast cancer-specific and allcause survival between European-American and African-American women in BCN.
Stage at diagnosis, age, race, socioeconomic status, lifestyle, and tumor characteristics
are all associated with breast cancer mortality and survival (37-45). The association
between geographic proximity to the screening referral provider, mammography facility,
and breast cancer mortality has not been elucidated.
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We found no significant difference in the survival proportions for breast cancerspecific and all-cause among AA and EA women. In the crude model, we found that
women living 10+ miles from the diagnosing mammography and closest mammography
facility had ~2-fold increase risk of death from breast cancer compared to those living
<10 miles. However, we found no association when adjusted for race, age, estrogen
receptor, marital status, income, insurance, treatment, and breast cancer stage at
diagnosis. We also found no association between travel distance to the screening referral
provider, diagnosing mammography facility, closest mammography facility and all-cause
mortality between EA and AA women. Though we did not find any study that
investigated travel distance to healthcare facility and breast cancer survival in the United
States, a study in Northern England had similar finding (46); they found no association
between travel time to the general practitioners and breast cancer survival. Our finding
shows that travel distance to the screening referral provider and mammography facility
may not be a risk factor for breast cancer mortality and survival among women in BCN.
Since our finding from aim 2 did not find any convincing evidence that travel distance to
the screening referral provider and mammography facility was associated with breast
cancer stage of diagnosis, we were not surprised with these null findings.
Implications
This dissertation provides significant contributions to the better understanding of
geographical level barriers to abnormal mammographic follow-up and breast cancer
morbidity and mortality, especially in South Carolina. Mammography screening rates
have improved among women; however, barriers affecting timely follow-up from an
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abnormal mammogram and breast cancer morbidity and mortality are still serious public
health concerns. The study showed that travel distance from patient residence to the
diagnosing mammography facility affects completion of abnormal mammographic
finding; women living farther from the facility had longer days to resolution (completion
of abnormal mammographic finding) compared to those who living the closest. This
study provides a geographical dimension that needs to be considered when developing
effective intervention to make sure women are having timely abnormal mammographic
finding. Due to the low-income population of the BCN program, some women may not
have reliable transportation. Hence, providing transportation, such as a shuttle, for
patients to and from the facility may be an effective intervention.
The establishment of BCN was to provide service delivery and ensures timely and
complete diagnostic follow-up and treatment initiation for underserved women screened
through the program. Since we found evidence of racial disparity in the time to
completion of abnormal mammogram work-up (AA women had longer days to
completion compared with EA women), additional support to the BCN program to
expand services should be promoted to reduce the disparity in days to completion of
abnormal mammographic finding among EA and AA women.
Living farther from the screening referral provider and mammography facility did
not increase the chance of late-stage breast cancer at diagnosis and mortality among
women in BCN. There were also no racial disparities in the breast cancer stage at
diagnosis and mortality among the women. These findings reveal that the program is
meeting established program standards of reducing health disparities among racial/ethnic
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groups. However, the findings in this study may be unique, because our population was
from a program that was established to provide adequate screening and follow-up among
women who enter the program; therefore, it may not be generalized to the general
population.
Another explanation for these null findings could be related to the geography of
South Carolina. The state is relatively a rural state and women may seek health services
no matter the distance. Due to the extensive BCN network providing service throughout
the state, travel distance may not be an issue for these women; the mean travel distance to
the screening provider is 10.9 miles (SD=10.5), diagnosing mammography facility is 14.6
miles (SD=15.8), and closest mammography facility is 8.1 miles (SD=6.5). Overall, this
study has shed some light on geographical proximity to some of the health facilities and
completion of abnormal mammographic finding and breast cancer morbidity and
mortality among women with homogenous socioeconomic status. This study adds to
some of the breast cancer disparities research in South Carolina.
Recommendations for Future Research
This research is the first study to use geospatial method to examined travel
distance to the screening provider, mammography facility, and completion of abnormal
mammography follow-up among a low-income population who have access to screening
at no cost. It is also one of the few research studies to examined travel distance to the
screening provider, mammography facility, and breast cancer morbidity and mortality.
This research measured the distance to mammography facilities using road network.
However, the variation of the route, speed limits or other barriers to travel was not
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considered. Future research that examines the relationship between travel distance to
mammography facility or health facilities should consider these barriers, because it
affects travel distance. Capturing an accurate measurement of travel distance/time will
help better understand whether location of the health facilities affect health outcome.
Other important factors to consider are the mode of transportation utilized by patients,
availability and frequency of transport services, quality of service provided in the
mammography facilities, and the nature of social constraints related to mammography
utilization.
This study was conducted on a population that came from a relatively rural area.
The attitude regarding health care services may be different from people living in more
urban areas. Further study on similar program like the BCN in other geographical
location and larger study from the general population should be investigated to confirm
the findings.
Though this research focused on the geographic aspect (travel distance) from the
patient’s residence to the health facilities, future research should also seek qualitative
aspects focusing on the provider-patient communications to follow-up. The patient,
provider, and system can all contribute to inadequate follow-up and morbidity and
mortality. A multi-discipline will not deepen our knowledge about barriers affecting
completion of abnormal mammographic finding and breast cancer morbidity and
mortality, but it may also suggest avenues of intervention to decrease the health
disparities related to breast cancer.
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